Method for improving cerebrospinal fluid and its device and system
By implanting enzymes and exosomes into mammalian subjects, a system was developed to treat CSF using enzymatic digestion and pumping technology. This solved the problem of removing toxic biomolecules from the subarachnoid space, achieving the improvement and recycling of CSF, and reducing neuronal death and disease symptoms.
Patent Information
- Application Number
- CN202080041867.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-14
- Filing Date
- 2020-04-10
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-04-10
AI Technical Summary
Existing technologies are insufficient to effectively remove toxic biomolecules, such as DPR and TDP-43, from the subarachnoid space of mammalian subjects, which lead to neuronal death in the pathology of neurodegenerative diseases, and traditional methods may cause complications.
Modifiers, such as enzymes and exosomes, are used to treat CSF by enzymatic digestion or by placing live cells in a tube. The modifiers are implanted in the body and come into contact with CSF, including the use of proteases such as trypsin and ciliary structures. CSF is treated through the tube to remove or degrade toxic biomolecules, and the flow of CSF is controlled by a pumping system.
It effectively reduces the concentration of toxic biomolecules in CSF, reduces neuronal death, reduces disease symptoms, lowers the risk of complications, and achieves improvement and recycling of CSF.
Smart Images

Figure CN114007665B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority and the benefit of U.S. Provisional Patent Application No. 62 / 832,486, filed April 11, 2019, the entire disclosure of which is incorporated herein by reference in its entirety. This application also claims priority and the benefit of U.S. Provisional Patent Application No. 62 / 960,861, filed January 14, 2020. Field of the Invention
[0003] Various embodiments of the present invention provide systems and methods for improving fluid in the subarachnoid space, and more specifically, provide methods and systems whereby improving agents arranged, placed or positioned on a structure in fluid communication with the subarachnoid space of a mammalian subject improve biomolecules contained within the subarachnoid space. Background Art
[0004] Many neurodegenerative diseases are associated with the accumulation of biomolecules (e.g., toxic proteins) contained in the cerebrospinal fluid (CSF) or other fluids (e.g., interstitial fluid) within the subarachnoid space (SAS) of a mammalian subject. Problematically, these (e.g., toxic) biomolecules may be secreted and transported by the CSF to other cells in the body, a process that may occur over several years. For example, dipeptide repeat proteins (DPRs) and / or TDP-43 have been implicated in neuronal death in the pathology of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), Alzheimer's disease (AD), frontotemporal lobar degeneration (FTD), Parkinson's disease (PD), Huntington's disease (HD), and progressive supranuclear palsy (PSP), to name a few. As a result, research has focused primarily on removing the offending DPRs. Techniques for removing DPRs and / or TDP-43 include: shunting CSF from the CSF space, diluting the CSF (e.g., with artificial fluids), administering drugs to the CSF, conditioning the CSF, and / or manipulating CSF flow. However, these conventional techniques often result in complications. Summary of the invention
[0005] Therefore, it would be desirable to provide in situ and other systems and methods to improve CSF and other fluids (eg, interstitial fluid) in the SAS by implanting the system or components thereof partially or completely in vivo (eg, completely or primarily within the SAS).
[0006] In a first aspect, some embodiments of the present invention relate to methods for treating a mammalian subject suffering from at least one of a pathology, trauma, a neurological disease, a non-neurological disease, or a defect characterized by the presence of toxic biomolecules in CSF. In some embodiments, the method includes improving toxic biomolecules in CSF using an improving agent, an improving technique, or a combination thereof (e.g., by enzymatically digesting toxic biomolecules and / or by placing pin1, exosomes, and / or living cells in a cylinder and circulating CSF through the cylinder). In some variations, enzymatic digestion of toxic biomolecules may include enzymatic digestion of toxic biomolecules using a protease. The improvement of toxic biomolecules may occur at least in part in: the ventricular space of the subject, the subarachnoid space of the subject's brain, and / or the lumbar region of the subject.
[0007] In some embodiments, the method can include the steps of: selecting a patient having at least one of the following symptoms: pathology, trauma, neurological disease (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), frontotemporal lobar degeneration (FTD), progressive supranuclear palsy (PSP), Huntington's disease (HD) and Parkinson's disease (PD), cancer, intracranial metastatic disease (IMD), diabetes, type 3 diabetes, lupus, poisoning, chronic traumatic encephalopathy (CTE), bacterial meningitis, aneurysm, stroke, cerebral vasospasm and traumatic brain injury), non-neurological disease, or defect; removing a volume (e.g., at a flow rate between about 0.1 mL / min and about 100 mL / min, between about 1 mL and about 200 mL) of CSF from a first location (e.g., a location in a lumbar CSF space); treating the CSF volume with a cartridge to treat (e.g., remove, reduce, alter, sequester, digest, neutralize or inactivate) the symptom, such as substance(s) (e.g., tau, cis p-tau, Abeta, TDP-43, SOD1, DPR, neurofilaments and alpha-synuclein), for example, by enzymatic activity; and returning the processed CSF volume to the patient at a second location (e.g., a location in the cervical CSF space or the ventricular CSF space). In some applications, embodiments of the method further include waiting a first length of time after removing a volume of fluid from the patient and / or waiting a second length of time after returning the processed fluid volume to the patient.
[0008] In some embodiments, the method may also include using a sensor to measure the characteristics of the processed CSF volume; and returning the processed CSF volume to the patient at a second position in the patient's cervical CSF space and / or ventricular CSF space. In some variations, due to the bidirectional and / or dual-flow characteristics of the method, in an alternative, a certain volume of CSF can be removed from the first position in the cervical CSF space and / or ventricular CSF space of the patient's position and the processed CSF volume to the patient can be returned to the second position in the patient's lumbar CSF space. In addition, CSF can flow through the enzyme cylinder reversibly once or multiple times to increase the residence time and therapeutic efficacy and effectiveness in the cylinder. Preferably, the processed CSF is returned to the patient at a rate substantially the same as the rate of removing the CSF volume. In some embodiments, these steps can occur at least partially simultaneously. Optionally, the method may include filtering the processed CSF with a getter to capture unbound enzymes before returning the processed CSF to the patient.
[0009] In some variations, the method further comprises updating one or more parameters of a set of therapeutic operating parameters based on the measured CSF characteristic meeting or exceeding a predetermined threshold.The operating parameters may be set to maintain a specific pressure and / or a specific volume.
[0010] In some embodiments, the method can include repeating the removal, processing, and return steps and / or updating a set of processing operating parameters (e.g., maintaining at least one of a specific pressure, a specific volume change, and a specific flow rate within the patient's CSF space) based on the measured fluid properties reaching or exceeding a predetermined threshold until one or more criteria are met.
[0011] In some variations, the CSF volume removed is greater than or equal to the processed CSF volume returned.Preferably, the CSF volume is returned to the patient at substantially the same rate as the CSF volume is removed from the patient.
[0012] In a second aspect, some embodiments of the present invention relate to a CSF improvement system for fluid communication with a mammalian subject (e.g., implanted (i.e., completely or partially) therein). In one embodiment, the system includes a substrate (e.g., a barrel) and an improvement agent. The improvement agent can be an enzyme disposed on the inner surface of the barrel and / or an enzyme decorated on the inner surface of the barrel. Alternatively, the improvement agent can include pin1, exosomes, and / or living cells disposed in the barrel.
[0013] In one embodiment, the improving agent modifies or degrades biomolecules present in CSF by enzymatic digestion, and in some variations, the enzyme used for enzymatic digestion can be a protease (e.g., trypsin; elastase; cathepsin; clostripain; calpains, including calpain-2; caspases, including caspase-1, caspase-3, caspase-6, caspase-7, and caspase-8; M24 homologs; human airway trypsin-like peptidase; proteinase K; thermolysin; Asp-N endopeptidase; chymotrypsin; LysC; LysN; glutamyl endopeptidase; staphylococcal peptidase; arg-C protease; proline endopeptidase; thrombin; cathepsin E, S, B, K, L1; Tissue Type A; heparinase; granzymes, including granzyme A; methotrexate alpha; pepsin; endothelial enzymes; kallikrein-6; kallikrein-5; and combinations thereof.
[0014] Exemplary embodiments of the substrate may include a foldable and / or flexible substrate to facilitate catheter-based implantation in a subject; a substrate comprising a plurality of cilia (e.g., ciliary projections extending from a shell portion, fibers and / or brush fibers that can be retracted and / or extended from within the substrate); beads (e.g., superparamagnetic beads) disposed within or on a substrate (e.g., a container); a dialysis membrane catheter; a tubular device containing a biomolecule improving agent; and / or a plurality of appendages.
[0015] In some applications, the system also includes a subcutaneous port for sampling CSF; introducing, removing or replenishing an improving agent; introducing or removing a substrate; introducing a drug; and / or maintaining a drug for a long time. In another application, the system may also include one or more CSF fluid circuits having an inlet and outlet port (e.g., a first inlet and outlet port and a second inlet and outlet port) to increase the flow of CSF through the substrate, and one or more of the following: a sensor located in the CSF circuit (e.g., a temperature sensor, a pressure sensor, a pH sensor, a UV sensor, an IR sensor, a turbulence sensor, a Raman scattering sensor, a dynamic light scattering sensor, a component concentration sensor, a flow sensor, and a combination thereof); a pump (e.g., a peristaltic pump, a rotary vane pump, an Archimedean screw, an airbag, an inflatable airbag, a hydraulic bag, a piston pump, an electric pump, a passive pump, an automatic pump, a valveless pump, a bidirectional pump, and a combination thereof); a valve (e.g., a one-way valve, a mitral valve, a tricuspid valve, a ruby valve, and a combination thereof); and / or an actuator located in the CSF circuit. Preferably, a system controller (eg, an open loop controller, a closed loop controller, a PID controller, a PID threshold controller, a system identification algorithm, and combinations thereof) may be operably coupled to one or more sensors, pumps, and / or actuators.
[0016] In some variations, the system may further include a support and / or pump (e.g., having porous walls) and / or an actuator such that the biomolecule improving agent is decorated on the inner surface of the pump, and more specifically, the biomolecule improving agent is retained by the porous wall.
[0017] In some applications, the system further comprises one or more of: a control system; a CSF guiding system; one or more of a cervical catheter, a lumbar catheter, or a ventricular catheter; and a sensor for measuring or sensing CSF composition and / or CSF properties. The control system can maintain CSF pressure and / or flow within the mammalian subject. In some variations, the control system has a programmable memory, a data processing system, and a communication subsystem, and the CSF guiding system has a pump; a conduit; a T-valve, a backflow prevention valve, and / or a shutoff valve; and an access port and / or a subcutaneous access port.
[0018] In some embodiments, processing a volume of CSF can include filtering the volume of CSF using at least one of size filtration, ion filtration, tangential flow filtration, countercurrent tangential flow filtration, ultrafiltration, slot filtration, in-line filtration, or cascade filtration. In other embodiments, processing a volume of CSF can include removing waste, subjecting a volume of CSF to enzymatic digestion, subjecting a volume of CSF to bioaffinity interactions with or without antibodies, subjecting a volume of CSF to ultraviolet radiation, subjecting a volume of CSF to heating or cooling or temperature changes, subjecting a volume of CSF to an electromagnetic field, subjecting a volume of CSF to a pressure change, subjecting a volume of CSF to a pH change, and / or subjecting a volume of CSF to an operating agent (e.g., magnetic beads, nanoparticles, optical tweezers, and combinations thereof), alone or in combination with a bioaffinity agent.
[0019] In some applications, the method may also include: maintaining the reduced toxic biomolecule content in the CSF after the initial toxic biomolecule content in the CSF is reduced; charge or size filtering the CSF to filter out toxic biomolecules; treating the CSF with antibodies or nanobodies to filter out toxic biomolecules; combining enzymatic and charge or size filtration methods to filter out toxic biomolecules; and / or increasing the naturally occurring (e.g., focused) flow of the CSF.
[0020] In some embodiments, the improving agent can be introduced into the CSF in the subarachnoid space of the subject. In other embodiments, the improving agent can be arranged on a firm, collapsible or flexible structure, which can be implanted in the subject (e.g., by catheter-based implantation). In some variations, the structure includes one or more of the following: substrate, cilia, cilia extending from substrate, fibers, fibers extending from substrate, branches, branches extending from substrate, fenestrations, beads, multiple beads, bistable overall structures, outcropping branches, stents, catheters, tubes, slurries and combinations thereof.
[0021] In some embodiments, the structure includes cilia on a surface (e.g., a hydraulically activatable surface, a pneumatically activatable surface, and / or a shape memory surface), which in some variations may include a shell surrounding an inner core. Using such a composition, the method may also include: expanding the shell forming cilia; expanding the inner core so that CSF located between the inner core and the shell is forced through the cilia; and shrinking the inner core and the shell.
[0022] In other embodiments, the structure can include fibers.Using such a composition, the method can include extending the fibers from within a delivery device into the CSF and retracting the fibers back into the delivery device.
[0023] In yet another embodiment, the structure can include an integral bistable structure with appendages formed thereon. Using such a composition, the method can include expanding the integral bistable structure to deploy the appendages into the CSF and emerging from the integral bistable structure, and collapsing the integral bistable structure to retract the appendages and provide mixing motion in the CSF.
[0024] In some embodiments of the method, the improvement technique includes introducing an improvement agent outside the subarachnoid space of the subject and allowing CSF to circulate (e.g., using an active or passive pump) through the improvement agent. In some embodiments, the embodiment includes returning the treated CSF to the subarachnoid space. In some applications, circulating CSF and returning the treated CSF may include delivering CSF (e.g., using a catheter) via multiple catheter insertion positions entering the subarachnoid space; delivering CSF (e.g., using a multi-lumen catheter arrangement) through a single catheter insertion position entering the subarachnoid space; and / or active circulation (e.g., by active or passive pumping) to maintain controlled fluid flow. In some embodiments, circulating CSF includes placing an improvement agent in a catheter or tube and allowing CSF to flow through the catheter or tube.
[0025] In a third aspect, some embodiments of the present invention relate to a CSF improvement system, which can be implanted (e.g., completely or partially) in a mammalian subject so as to be in fluid communication with a mammalian subject. In some embodiments, the system is operable to provide a centralized flow of CSF and is configured to include: a flow controller, a catheter, a pump, and / or a structure to change the fluid flow rate. Optionally, the system may also include a catheter at different fluid entry points in the subarachnoid space (e.g., in the lateral ventricle and the lumbar sac, in the cisterna magna and the lumbar sac, in the cisterna magna and the frontal lobe, in the lateral temporal subarachnoid space, and / or in the cervical subarachnoid space and the lumbar sac). In some embodiments, one or more passive pumps, internal active pumps, and / or passive flow regulators may be substantially implanted in the subarachnoid space.
[0026] In a fourth aspect, some embodiments of the invention relate to a CSF improvement system that can be implanted (e.g., completely or partially) in a mammalian subject so as to be in fluid communication with the mammalian subject. In some embodiments, the system is configured to provide a centralized flow of CSF and includes a substrate; an improvement agent disposed on and / or in the substrate; and one or more flow controllers, conduits, pumps, and / or structures to change fluid flow.
[0027] In a fifth aspect, some embodiments of the present invention relate to a method for treating a mammalian subject suffering from at least one of a pathology, trauma, a neurological disease, a non-neurological disease, or a defect characterized by the presence of toxic biomolecules in the CSF. In some embodiments, the method includes improving toxic biomolecules in the CSF using an improving agent, an improving technique, or a combination thereof (e.g., by enzymatic digestion of toxic biomolecules and / or by placing pin1, exosomes, and / or living cells in a cylinder and circulating the CSF through the cylinder). In some variations, enzymatic digestion of toxic biomolecules may include enzymatic digestion of toxic biomolecules using a protease. The improvement of toxic biomolecules may occur at least in part in: the ventricular space of the subject, the subarachnoid space of the subject's brain, and / or the lumbar region of the subject. In certain applications, the method may include causing the CSF to flow reversibly through the enzyme cylinder.
[0028] In yet another embodiment of the method, the improved technique includes circulating CSF in a flow from a first location in the subarachnoid space to a second location in the subarachnoid space (e.g., actively delivering CSF using an automated balloon pump). In some variations, the flow is substantially maintained within the subarachnoid space. In some applications, the method also includes enabling CSF to circulate outside the subarachnoid space or circulating CSF at a natural flow rate. The circulation can be from a first location with a low biomolecule concentration to a location with a high biomolecule concentration or from a first location with a high biomolecule concentration to a location with a low biomolecule concentration.
[0029] In another embodiment, the method includes enhancing (eg, the phase, direction and / or amplitude of CSF flow) the naturally occurring (eg, focused) flow of CSF. In some applications, the method may further include circulating an improving agent through the CSF of the subject.
[0030] In yet another embodiment, the method may include circulating the improver through the CSF of the experimenter. In various applications, the improver may circulate through the CSF flowing with the natural flow level, the improver may circulate through the CSF outside the experimenter's subarachnoid space, and / or the improver may circulate through the CSF in the experimenter's subarachnoid space substantially. In some variations, circulating the improver through the CSF in the subarachnoid space may include applying the improver to a plurality of beads, introducing the beads into the CSF in the subarachnoid space (e.g., by including the beads in a dialysis membrane catheter or a porous bag, by introducing the beads into the slurry, including the beads in a tubular device, and / or by including the beads in a multi-lumen catheter), and moving the beads. Alternatively, a syringe may be used to add or remove beads.
[0031] In some applications, when using a multi-lumen catheter, the method may include introducing beads from a supply reservoir into a first lumen of the multi-lumen catheter, circulating the beads through the first lumen and through the second lumen of the multi-lumen catheter, and introducing the beads from the second lumen into a receiving reservoir. In addition, circulating the improving agent through the CSF outside the subarachnoid space may include applying the improving agent to a plurality of beads, introducing the beads into the CSF outside the subarachnoid space, and circulating the beads. In some variations, the first lumen and the second lumen of the multi-lumen catheter include holes whose size allows CSF biomolecules to pass through the holes while preventing the beads from passing through the holes. In other variations, the multi-lumen catheter is operable to allow countercurrent flow.
[0032] In a sixth aspect, some embodiments of the invention relate to methods for treating a mammalian subject suffering from a neurological or non-neurological pathology, a neurological or non-neurological trauma, or a neurological or non-neurological defect. In some embodiments, the method comprises circulating CSF in a subject with a focused flow. In some applications, an improving agent, an improving technique, or a combination thereof, is used to improve toxic biomolecules in the CSF. In other embodiments, no improving agent is used. In some embodiments, circulating CSF with a focused flow comprises: circulating CSF at a natural flow level, allowing CSF to flow out of the subarachnoid space, limiting CSF to flow only within the subarachnoid space, and / or using a passive pump.
[0033] In the seventh aspect, some embodiments of the present invention relate to a kit for improving the fluid extracted from a mammalian subject. In some embodiments, the kit includes a ventricular line section removably attached to a first position of the subject, a lumbar line section removably attached to a second position of the subject, a circulatory system in fluid communication between the ventricular line section and the lumbar line section, monitoring hardware including a tube operably connected to the circulatory system, wherein the tube contains an improver for improving the fluid, and a pumping device for extracting fluid, circulating the fluid and returning the fluid to the subject. In some embodiments, the ventricular line section may include a ventricular catheter, a catheter adapter removably attached to the ventricular catheter, a subcutaneous access port, and a subcutaneous access needle. In some embodiments, the lumbar line section may include a lumbar catheter, a catheter adapter removably attached to the lumbar catheter, a subcutaneous access port, and a subcutaneous access needle. Optionally, the ventricular line section and / or the lumbar line section may include a peritoneal catheter. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] The various features and advantages of various embodiments and implementations of aspects of the present invention, as well as the invention itself, may be more fully understood from the following description of the various presented embodiments when read in conjunction with the accompanying schematic drawings, in which:
[0035] Figure 1A shows a schematic diagram of a passive substrate having a plurality of cilia decorated with an improving agent after expansion of a shell according to some embodiments of the present invention;
[0036] Figure 1B shows the kernel expansion after some embodiments according to the present invention Figure 1A Schematic diagram of a passive substrate;
[0037] Figure 1C Figure 2 shows the core and shell after shrinking according to some embodiments of the present invention. Figure 1B Schematic diagram of a passive substrate;
[0038] FIG2A shows a schematic diagram of a static (reduced) state of an overall bistable structure having a plurality of cilia coated with an improvement agent formed on a plurality of appendages according to some embodiments of the present invention;
[0039] FIG2B shows a schematic diagram of an inset of a gap between a pair of appendages of FIG2A according to some embodiments of the present invention;
[0040] FIG2C shows a schematic diagram of an expanded state of the overall bistable structure of FIG2A according to some embodiments of the present invention;
[0041] Figure 3 A schematic diagram showing a porous flexible structure decorated with an improving agent according to some embodiments of the present invention;
[0042] FIG4A shows a schematic diagram of a tubular structure (e.g., a catheter) comprising a plurality of shrink fibers decorated with an improving agent according to some embodiments of the present invention;
[0043] FIG. 4B shows a schematic diagram of the tubular structure of FIG. 4A with fibers decorated with a modifying agent extending into the CSF space according to some embodiments of the present invention;
[0044] Figure 5 shows a schematic diagram of a coated stent placed in a cerebral aqueduct according to some embodiments of the present invention;
[0045] Figure 6 shows a schematic diagram of a system combining an enzymatic filter and a size filter according to some embodiments of the present invention;
[0046] Fig. 7A A schematic diagram showing a side view of a hydraulic peristaltic pump according to some embodiments of the present invention;
[0047] Figure 7B Shows Figure 7B A schematic top view of a peristaltic pump;
[0048] Fig. 8A shows a schematic diagram of a first stage of a passive pump that uses normal pressure fluctuations in a SAS fluid to drive fluid through the pump according to some embodiments of the present invention;
[0049] Figure 8B The invention shows the use of normal pressure fluctuations in a SAS fluid to drive the fluid through a pump according to some embodiments of the present invention. Fig. 8A Schematic diagram of the second stage of the passive pump;
[0050] Figure 8C The invention shows the use of normal pressure fluctuations in a SAS fluid to drive the fluid through a pump according to some embodiments of the present invention. Fig. 8A Schematic diagram of the third stage of the passive pump;
[0051] Fig.8D shows a schematic diagram of a passive pump with a porous separator according to some embodiments of the present invention;
[0052] Fig. 8E An image showing an open-ended balloon catheter pump according to some embodiments of the present invention;
[0053] Figure 8F An image showing a closed-end balloon catheter pump according to some embodiments of the present invention;
[0054] Fig. 9Ashows a schematic diagram of a structure for actively pumping fluid from a left bladder to a right bladder according to some embodiments of the present invention;
[0055] Fig. 9B FIG. 1 shows a static or intermediate (no flow) state according to some embodiments of the present invention. Fig. 9A A schematic diagram of the structure of
[0056] Fig. 9C A method for actively pumping fluid from the right bladder to the left bladder is shown according to some embodiments of the present invention. Fig. 9A A schematic diagram of the structure of
[0057] Fig. 10A A schematic diagram showing a first improved system having a large flow system according to some embodiments of the present invention is shown;
[0058] Fig. 10B shows a schematic diagram of a second improved system having a large flow system substantially implanted within the SAS according to some embodiments of the present invention;
[0059] Fig.11 shows a schematic diagram of a multi-lumen catheter comprising a plurality of circulation beads decorated with an improving agent according to some embodiments of the present invention;
[0060] Fig. 12A shows a schematic diagram of a system for delivering a focused flow across the motor cortex according to some embodiments of the present invention;
[0061] Fig. 12B shows a schematic diagram of a first system for delivering focused flow from a ventricular region to a lumbar region according to some embodiments of the present invention;
[0062] Fig. 12C shows a schematic diagram of a second system for delivering focused flow from the ventricular region to the lumbar region according to some embodiments of the present invention;
[0063] Fig.12D shows a schematic diagram of a third system for delivering focused flow from the ventricular region to the lumbar region according to some embodiments of the present invention;
[0064] Fig.13 shows a schematic diagram of a pressurized chamber automatic pump with a flexible closed loop cartridge according to some embodiments of the present invention;
[0065] Fig.14A shows a schematic diagram of a pressurized chamber automatic pump with a balloon-filled cartridge (stationary) according to some embodiments of the present invention;
[0066] Fig. 14BA diagram showing a collapsed balloon due to an increase in ambient pressure according to some embodiments of the present invention. Fig.14A Schematic diagram of the automatic pump for the pressurized chamber;
[0067] Fig. 14C FIG. 1 shows a method of expanding a balloon due to a drop in ambient pressure according to some embodiments of the present invention. Fig.14A Schematic diagram of the automatic pump for the pressurized chamber;
[0068] Fig.15A A schematic diagram of an exemplary system for in vitro improvement of a fluid (e.g., CSF) according to some embodiments of the present invention is shown;
[0069] Fig. 15B Some embodiments of the present invention are shown for use in Fig.15A Schematic diagrams of the control system and pump system of the illustrated system from front and rear views;
[0070] Fig. 15C Some embodiments of the present invention are shown for use in Fig.15A A schematic diagram of a fluid directing system of the system shown;
[0071] Fig.16 The use of some embodiments according to the present invention is shown Fig.15A A flow chart of a method for improving CSF in vitro is shown in the system;
[0072] Fig.17 shows a schematic diagram of a three-stage tangential flow filtration subsystem integrated with an enzyme cartridge and subsequent extractant according to some embodiments of the present invention;
[0073] Fig.18 shows a schematic diagram of a cartridge according to some embodiments of the present invention; and
[0074] Fig.19 A block diagram of an improvement kit according to some embodiments of the present invention is shown. DETAILED DESCRIPTION
[0075] Although embodiments of the present invention will be described primarily in terms of treating neurological diseases in fluids, more specifically, in terms of improving the cerebrospinal fluid (CSF) of mammalian subjects, the systems, methods, and techniques described herein are equally applicable to non-neurological diseases and disorders, as well as applications and conditions (e.g., cancer, intracranial metastatic disease (IMD), diabetes, type 3 diabetes, lupus, poisoning, chronic traumatic encephalopathy (CTE), bacterial meningitis, aneurysms, stroke, cerebral vasospasm, traumatic brain injury, rheumatoid arthritis, drug overdose, certain trauma, etc.). In addition, embodiments of the present invention are also applicable to conditions and applications in living cells. For example, certain embodiments and applications or implementations of the present invention can provide entry points for delivering living cells or exosomes to fluids (e.g., CSF) and the nervous system. More specifically, living cells or other organisms (e.g., yeast, bacteria, viruses, etc.) can be placed in an external (extracorporeal) cylinder to provide secreted products that can benefit, for example, the health of the central nervous system. CSF can be conveyed through a cylinder containing living cells.
[0076] definition
[0077] As used in this specification and the appended claims, the following terms shall have the meanings indicated, unless the context otherwise requires or a different meaning is clear:
[0078] Biomolecule refers to any molecule that can be produced by or is similar to a living system (i.e., an organism). For purposes of illustration and not limitation, biomolecules may include RNA, DNA, proteins, peptides, lipids, carbohydrates, polysaccharides, nucleic acids, oligonucleotides, antisense oligonucleotides, polynucleotides, amino acids, enzymes, antibodies, nanobodies, molecularly imprinted polymers, primary metabolites, secondary metabolites, and natural products;
[0079] Fluid refers to any flowable biological medium, such as that present in the subarachnoid space or elsewhere in a subject, and includes cerebrospinal fluid (CSF), interstitial fluid (ISF), blood, sweat, tears, semen, lymph, urine, breast milk, etc.;
[0080] The cerebrospinal fluid space refers to the volume inside the blood-brain barrier, including the subarachnoid space;
[0081] A subject or patient is a mammal (e.g., a human or an animal) who is undergoing medical treatment, diagnosis, monitoring, research, or care;
[0082] In vitro means occurring outside the body of a mammal, and is used interchangeably herein with the terms ex vivo and ex vivo; and
[0083] In situ refers to occurring within the body of a mammal and can be used interchangeably with the term in vivo.
[0084] improve
[0085] Embodiments of the present invention provide systems and methods for improving fluids (e.g., cerebrospinal fluid (CSF), interstitial fluid (ISF), blood, etc.) in the subarachnoid space (SAS) of a mammalian subject, generally referred to herein as CSF unless otherwise specifically distinguished (e.g., referred to only as CSF). Representative systems can be implanted in whole or in part in the body of a mammalian subject. In vivo, the system and / or its components can also be implanted in whole or in part in the SAS. The method may include steps that may occur entirely in vivo or may include some steps that occur in vitro.
[0086] For purposes of illustration and not limitation, improvement may include changing the physical parameters of a fluid, as well as digesting, removing, fixing, reducing and / or changing to become more acceptable and / or inactivating certain entities, including: target molecules, proteins, aggregates, viruses, bacteria, cells, counterparts, enzymes, antibodies, substances and / or any combination thereof. For example, in some embodiments and applications of the present invention, improvement may refer to the removal of toxic proteins or conditioning one or more of them from blood, interstitial fluid, or lymph or other fluids contained therein, and the effect of such removal on the treatment of diseases or conditions that affect various body functions (i.e., improving the clinical condition of the patient). In addition, the improvement can be performed by any of the following: digestion, enzymatic digestion, filtration, size filtration, tangential flow filtration, countercurrent cascade ultrafiltration, centrifugation, separation, magnetic separation (including with nanoparticles, etc.), electrophysical separation (by one or more of enzymes, antibodies, nanobodies, molecularly imprinted polymers, ligand-receptor complexes and other charge and / or bioaffinity interactions), photonic methods (including fluorescence activated cell sorting (FACS), ultraviolet (UV) sterilization and / or optical tweezers), photoacoustic interactions, chemical treatments, thermal methods and combinations thereof. Advantageously, various embodiments or implementations of the present invention can reduce the level of toxicity and, once reduced, help maintain the reduced level over time.
[0087] The degree of improvement reflected by the concentration of the target biomolecule can be detected in a variety of ways. These include optical techniques (e.g., Raman, coherent Stokes and anti-Stokes Raman spectroscopy; surface-enhanced Raman spectroscopy; diamond nitrogen vacancy magnetometry; fluorescence correlation spectroscopy; dynamic light scattering, etc.) and the use of nanostructures, such as carbon nanotubes, enzyme-linked immunosorbent assay, surface plasmon resonance, liquid chromatography mass spectrometry, cyclic proximity ligation assay, etc.
[0088] Improvement may include the use of treatment systems (eg, UV radiation, IR radiation) as well as substances whose properties make them suitable for improvement.
[0089] Improvement of CSF or improved CSF - these terms are used interchangeably herein - refers to a treated volume of CSF from which one or more target compounds have been partially, largely or completely removed. It should be understood that the term removal as used herein may refer not only to spatial separation, such as entrainment, but also to effective removal by sequestering, fixing or transforming a molecule (e.g., by shape change, denaturation, digestion, isomerization or post-translational modification) to make it less toxic, non-toxic or insignificant.
[0090] Improvers are any materials or processes that can improve fluids, including enzymes, antibodies or antibody fragments, nucleic acids, receptors, antibacterial, antiviral, anti-DNA / RNA, proteins / amino acids, carbohydrates, enzymes, isomerases, compounds with high and low biospecific binding affinity, aptamers, exosomes, ultraviolet light, temperature changes, electric fields, molecularly imprinted polymers, living cells, etc.
[0091] Improved by enzyme digestion
[0092] Improvement of biomolecules in CSF can also be achieved through enzymatic digestion, so that in some embodiments and applications, the improver modifies or degrades biomolecules in CSF. To this end, enzyme-substrate pairs can be selected by panel and counter panel search. For example, candidate enzyme groups for digesting biomolecules can be graded according to stability, commercial availability, and related interaction mechanisms, while counter groups can ensure that candidate enzymes do not affect substances in CSF that should not be changed by enzymes. Alternatively, enzymes can be found by microbial screening, such as mutant hunting or nitrogen activity determination. In yet another embodiment, enzymes can be selected by biomolecular engineering computational models.
[0093] Improved methods and improved chemistry are described in International Patent Application Nos. PCT / US2019 / 042880 and PCT / US2019 / 042879, filed on July 22, 2019, and entitled “Methods of Treating Neurological Disorders,” the disclosures of which are incorporated herein by reference in their entirety.
[0094] In some embodiments, agents for improving the system may include: trypsin; elastase; clostripain; calpains, including calpain-2; cysteine proteases, including cysteine proteases-1, cysteine proteases-3, cysteine proteases-6, cysteine proteases-7 and cysteine proteases-8; M24 homologs; human airway trypsin-like peptidase; proteinase K; thermolysin; Asp-N endopeptidase; chymotrypsin; LysC; LysN; glutamyl endopeptidase; staphylococcal peptidase; arg-C protease; proline endopeptidase; thrombin; cathepsin, including cathepsin E, S, B, K or L1; Tissue Type A; heparinase; granzymes, including granzyme A; methotrexate alpha; pepsin; endothelial enzymes; kallikrein-6; kallikrein-5; and combinations thereof. In other embodiments, pin1, exosomes and / or living cells may be used as improving agents.
[0095] Modification of toxic proteins
[0096] Various applications of the present invention provide methods for treating neurological disorders or related conditions characterized by the presence of toxic proteins in CSF, the methods comprising: contacting CSF of a subject in need thereof with an effective amount of a post-translational modification protein capable of modifying the toxic protein, thereby reducing the concentration of the toxic protein, in situ or otherwise.
[0097] In some embodiments, the substrate, target molecule or substance may include: beta-amyloid protein (any species or form), TDP43 (e.g., misfolded TDP-43 protein, such as mutant TDP-43 protein), or active oxidative species of tau (or any number of hyperphosphorylated tau isoforms) (e.g., tau protein aggregates, tau protein tangles, tau oligomers, hyperphosphorylated tau protein, soluble tau protein, tau dimers, cis-pTau)) protein, inflammatory mediators (e.g., cytokines, including TNF-a, IL-67, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36, IL-37, IL-38, IL-39, IL-40, IL-50, IL-51, IL-61, IL-70, IL-71, IL-81, IL-19, IL-19 -1, IL-2, IL-6, IL-12, interferon-γ, etc.), α-synuclein (including peptides or oligomers), insoluble superoxide dismutase-1 (SODI) (e.g., mutant or misfolded wild-type SOD1 protein), glutamate, neurofilament protein and anti-GMI ganglioside antibodies, anti-AGM1 ganglioside antibodies and sulfatides, blood cells (e.g., red blood cells), oxygenated hemoglobin, endothelin, inflammatory mediators, bacterial or viral entities, tumor necrosis factor-α (TNFa) and IgG, cells and inflammatory mediators include but are not limited to C5a, TNFa, IL 2, IL-6, interferon-γ, IgG and endotoxin, T cells, B cells, anti-myelin antibodies and inflammatory mediators, including but not limited to TNFa, IL 2, IL-6, interferon-γ, endothelin and enolase, DPR, circulating tumor cells. In certain embodiments, the toxic protein is a mutated FUS / TLS protein. In certain embodiments, the toxic protein is in a toxic form.
[0098] The microtubule-associated protein tau is the main component of neurofibrillary tangles (NFTs) associated with AD and tauopathies, which are characterized by tau hyperphosphorylation and aggregation. Tau is an essentially unstructured protein due to its very low hydrophobic content containing projection domains, regions rich in basic proline, and assembly domains. Tau is known to have a variety of post-translational modifications, such as acetylation, deamidation, glycation, glycosylation, isomerization, methylation, nitration, phosphorylation, proteolysis, threosylation, and ubiquitination. Hyperphosphorylation of tau, especially in the assembly domain, reduces the affinity of tau for microtubules and weakens its ability to regulate microtubule dynamics and axonal transport. In addition, parts of the basic proline-rich domain and pseudo-repeats also stabilize microtubules by interacting with their negatively charged surfaces. Alternative splicing of the two N-terminal insertion regions and the second, third, and tenth exons of tau leads to six tau isoforms of different lengths in the CNS. Depending on the alternative splicing of exon 10, the assembly domain of the carboxyl-terminal portion of the protein contains three or four repeats (3R or 4R) of a conserved tubulin-binding motif. The 4R isoform of Tau has a stronger ability to bind and stabilize microtubules than the 3R isoform. The adult brain has similar levels of 3R and 4R isoforms, while only 3R tau is expressed in the fetal stage. In tau pathologies, mutations that alter tau transcript splicing and the ratio of 3R to 4R tau isoforms are sufficient to cause neurodegenerative diseases. In addition to isoforms of full-length tau protein, certain tau fragments (e.g., fragments produced by cleavage by endogenous proteases) may also exhibit a tendency to aggregate or aggregate, the ability to promote the aggregation or aggregation of another tau isoform or fragment, and / or the ability to spread tau aggregation or aggregation to other cells, thereby causing neurotoxicity. Such tau fragments include, but are not limited to, fragments 14-441, 26-230, 1-314, 26-44, 1-44, 1-156, 45-230, 243-441, 256-441, 256-368, 1-368, 1-421, 151-421, 1-391, and X-441, where X is any integer from 182 to 194 (amino acid positions are numbered according to the sequence of the 2N4R isoform). In addition to these tau fragments, certain other fragments, such as fragments 124-441 and 1-402 (amino acid positions according to the sequence numbering of the 2N4R isoform), can be used as biomarkers for diagnosing neurological diseases or monitoring the progress or response of patients to treatment. Post-translational modifications of tau, such as phosphorylation and isomerization (cis or trans isomeric forms), can also greatly affect the aggregation ability of tau. For example, hyperphosphorylation of tau at serine and threonine residues before proline (pSer / Thr-Pro) results in insolubility and leads to neurofibrillary tangles (NFTs).Tau phosphorylation specific to Thr231-Pro is able to bind to the prolyl isomerase Pin1, which catalyzes the conversion between cis and trans. Phosphatases, such as PP2A, catalyze the dephosphorylation of tau only in the trans form. In summary, tau in human brain tissue can exist in a variety of different lengths and forms and have a variety of post-translational modifications. As used herein, the term "tau" includes various isoforms and fragments of tau protein with one or more post-translational modifications and in any folding state. When tau progresses from normal to NFT, it goes through a 'soluble' state in which the protein may be hyperphosphorylated, mislocalized, conformationally changed and / or oligomerized but has not yet formed a filament.
[0099] Post-translational modified proteins
[0100] In some embodiments, embodiments of the present invention provide a method for treating a neurological disorder or related condition characterized by the presence of a toxic protein in CSF, the method comprising: contacting the CSF of a subject in need thereof with an effective amount of a post-translationally modified protein capable of modifying the toxic protein, thereby reducing the concentration of the toxic protein.
[0101] In some variations, this embodiment also provides a composition comprising CSF of a subject having a neurological disorder or related condition, characterized by the presence of a toxic or pre-toxic form of a toxic protein in the CSF, and capable of modifying the toxic protein to reduce the concentration of the toxic protein.
[0102] The selective alteration of the post-translational modification protein of the present embodiment to the toxic or pre-toxic form of the toxic protein is achieved by a combination of substrate selectivity (post-translational modification proteins that preferentially recognize toxic or pre-toxic forms of proteins), active site specificity (post-translational modification proteins with specificity for cleaving peptide bonds of residue motifs encountered in toxic or pre-toxic forms of toxic proteins), substrate affinity (based on binding kinetics) and enzyme efficiency (enzyme reaction rate). In certain embodiments of the present invention, the post-translational modification protein is a mammalian, microbial (e.g., fungal, bacterial or viral) or plant protein.
[0103] In other aspects and embodiments of the invention, the post-translationally modified protein can be a phosphatase, an isomerase, an ubiquitin activating enzyme (E1), an ubiquitin conjugating enzyme (E2), an ubiquitin ligase (E3), a kinase, an acetylase, a deacetylase, a glycosylase or a deglycosylase.
[0104] Phosphatase
[0105] Phosphatases are enzymes that remove phosphate groups from phosphorylated amino acid residues of substrate proteins. In certain variations of embodiments of the invention, the post-translational modification protein is a phosphatase selected from the list comprising: PP1, PP2A, PP2B, PP4, PP5, PP6, PP7, PP2C, VHR, DUSP1, DUSP2, DUSP3, DUSP4, DUSP5, DUSP6, DUSP7, DUSP8, DUSP9, DUSP10, DUSP11, DUSP12, DUSP13, DUSP14, DUSP15, DUSP16, DUSP17, DUSP18, DUSP19, DUSP20, DUSP21, DUSP22, DUSP23, DUSP24, DUSP25, DUSP26, DUSP27, DUSP28, PHP, PPP1CA, PPP1CB, PPP29, PPP30, PPP31, PPP32, PPP33, PPP34, PPP35, PPP36, PPP37, PPP38, PPP39, PPP40, PPP41, PPP42, PPP43, PPP44, PPP45, PPP46, PPP47, PPP48, PPP49, PPP50, PPP51, PPP52, PPP53, PPP54, PPP55 1CC, PPP2CA, PPP2CB, PPP3CA, PPP3CB, PPP3CC, PPP4C, PPP5C, PPP6C, CDC14A, CDC14B, CDC14C, CDKN3, PTEN, SSH1, SSH2, SSH3, CTDP1, CTDSP1, CTDSP2, CTDSPL, DULLARD, EPM2 A. ILKAP, MDSP, PGAM5, PHLPP1, PHLPP2, PPEF1, PPEF2, PPM1A, PPM1B, PPM1D, PPM1E, PPM1F, PPM1G, PPM1H, PPM1J, PPM1K, PPM1L, PPM1M, PPM1N, PPTC7, PTPMT1, SSU72, and UBLCP1.
[0106] Isomerase
[0107] Isomerases are enzymes that catalyze the conversion of molecules from one isomeric structure to another. Intramolecular bonds break and form during the isomerization process, resulting in molecules with the same molecular formula but different bond connections or spatial arrangements. In certain embodiments of various embodiments, the post-translational modification protein is an isomerase selected from a list including: FK506 binding protein 4 (FKBP52), FK506 binding protein 51 (FKBP51, also known as FKBP5), FK506 binding protein (FKBP12), peptidyl prolyl cis / trans isomerase NIMA interacting 1 (Pin1), alanine racemase, methionine racemase, lactate racemase, tartrate epimerase, ribulose phosphate 3-epimerase, UDP-glucose 4-epimerase, methylmalonyl CoA epimerase, hydantoin racemase (hydantoin racemase), maleate isomerase, maleylacetoacetate isomerase, maleylpyruvate isomerase, linoleate isomerase, furanylfuroamide isomerase, peptidylprolyl isomerase, farnesol 2-isomerase, 2-chloro-4-carboxymethylenebut-2-ene-1,4-olide isomerase, ζ-carotene isomerase, lycopene isomerase, β-carotene isomerase, triose-phosphate isomerase, nuclear Sugar-5-phosphate isomerase, phenylpyruvate tautomerase, oxaloacetate tautomerase, steroid δ-isomerase, L-dopachrome isomerase, protein disulfide isomerase, prostaglandin-D synthase, allene oxide cyclase, lysophosphatidyl phosphatidyl mutase, precorrin-8X methyl mutase, phosphoglucomutase, phosphopentyl mutase, β-lysine 5,6-aminomutase, tyrosine 2,3-amino mutase, (hydroxyamino)benzene mutase, isochorismate synthase, methylaspartate mutase, chorismate synthase, muconate cycloisomerase, 3-carboxy-cis, cis-muconate cycloisomerase, tetrahydroxypteridine cycloisomerase, inositol-3-phosphate synthase, carboxy-cis, cis-muconate cyclase, chalcone isomerase, chloromuconate cycloisomerase, (+)-bornyl phosphate synthase, cycloeucalyptol cycloisomerase, α-pinene oxide decyclase, Dichloromuconate cycloisomerase, copalyl diphosphate synthase, internal copalyl diphosphate synthase, copalyl-diphosphate synthase, terpenoid diphosphate synthase, halimadienyl-diphosphate synthase, (S)-β-macrocarpene synthase, prolycopene ε-cyclase, prolycopene β-cyclase, prosolanapyrone-III cycloisomerase, and D-ribopyranase. In certain embodiments, the isomerase is Pin1.
[0108] Ubiquitinase
[0109] Ubiquitination is a post-translational modification in which the small regulatory protein ubiquitin is attached to target lysine residues of protein substrates. Ubiquitination involves multiple steps, activation (performed by ubiquitin activating enzyme E1), conjugation (performed by ubiquitin conjugating enzyme E2), and ligation (performed by ubiquitin ligase E3).
[0110] In certain applications of various embodiments, the post-translational modification protein is a ubiquitinating enzyme selected from the list consisting of: an E1 ubiquitin activating enzyme, such as UBA1, UBA2, UBA3, UBA5, UBA6, UBA7, ATG7, NAE1, SAE1; an E2 ubiquitin conjugating enzyme, such as UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2D4, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2M, UBE2N, UBE2O, UBE2Q1, UBE2Q2, UBE2R1 (CDC34), UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, UFC1; and E3 ubiquitin ligases such as AFF4, AMFR, ANAPC11, ANKIB1, AREL1, ARIH1, ARIH2, BARD1, BFAR, BIRC2, BIRC3, BIRC7, BIRC8, BMI1, BRAP, BRCA1, CBL, CBLB, CBLC, CBLL1, CCDC36, CCNB1IP1, CGRRF1 , CHFR, CNOT4, CUL9, CYHR1, DCST1, DTX1, DTX2, DTX3, DTX3L, DTX4, DZIP3, E4F1, FANCL, G2E3, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, H ERC1, HERC2, HERC3, HERC4, HERC5, HERC6, HLTF, HUWE1, IRF2BP1, IRF2BP2, IRF2BPL, ITCH, KCMF1, KMT2C, KMT2D, LNX1, LNX2, LONRF1, LONRF2, LONRF3, LRSAM1, LTN1, MAEA, MAP3K1, MARCH1, MARCH10, MARCH11, MARCH2, MARCH3, MARCH4, MARCH5, MARCH6, MARCH7, MARCH8, MARCH9, MDM2, MDM4, MECOM, MEX3A , MEX3B, MEX3C, MEX3D, MGRN1, MIB1, MIB2, MIDI, MID2, MKRN1, MKRN2, MKRN3, MKRN4P, MNAT1, MSL2, MUL1, MYCBP2, MYLIP, NEDD4, NEDD4L, NEURL1, NEURL1 B.NEURL3、NFX1、NFXL1、NHLRC1、NOSIP、NSMCE1、PARK2、PCGF1、PCGF2、PCGF3、PCGF5、PCGF6、PDZRN3、PDZRN4、PE LI1、PELI2、PELI3、PEX10、PEX12、PEX2、PHF7、PHRF1、PJA1、PJA2、PLAG1、PLAGL1、PML、PPIL2、PRPF19、RAD18、R AG1, RAPSN, RBBP6, RBCK1, RBX1, RC3H1, RC3H2, RCHY1, RFFL, RFPL1, RFPL2, RFPL3, RFPL4A, RFPL4AL1, RFPL4B, RFWD2, RFWD3, RING1, RLF, RLIM, RMND5A, RMND5B, RNF10, RNF103, RNF11, RNF111, RNF112, RNF113A, RNF113B NF114、RNF115、RNF121、RNF122、NF123、RNF125、RNF126、RNF128、RNF13、RNF130、RNF133、RNF135、RNF138、RNF 139、RNF14、RNF141、RNF144A、RNF144B、RNF145、RNF146、RNF148、RNF149、RNF150、RNF151、RNF152、RNF157、RNF149 F165、RNF166、RNF167、RNF168、RNF169、RNF17、RNF170、RNF175、RNF180、RNF181、RNF182、RNF183、RNF185、RNF 186、RNF187、RNF19A、RNF19B、RNF2、RNF20、RNF207、RNF208、RNF212、RNF212B、RNF213、RNF214、RNF215、RNF21 6、RNF217、RNF219、RNF220、RNF222、RNF223、RNF224、RNF225、RNF24、RNF25、RNF26、RNF31、RNF32、RNF34、RNF38、RNF39、RNF4、RNF40、RNF41、RNF43、RNF44、RNF5、RNF5 6、RNF7、RNF8、RNFT1、RNFT2、RSPRY1、SCAF11、SH3RF1、SH3RF2、SH3RF3、SHPRH、SIAH1、SIAH2、SIAH3、SMURF1、SMURF2、STUB1、SYVN1、TMEM129、TOPORS、TRAF2、TRAF3<h2 style=";text-align:left;direction:ltr">TRAF4、TRAF5、TRAF6、TRAF7、TRAIP、TRIM10、TRIM11、TRIM13、TRIM15、TRIM17、TRIM2、TRIM21、TRIM22、TRIM23、TRIM 24、TRIM25、TRIM26、TRIM27、TRIM28、TRIM3、TRIM31、TRIM32、TRIM33、TRIM34、TRIM35、TRIM36、TRIM37、TRIM38、TRIM 39、TRIM4、TRIM40、TRIM41、TRIM42、TRIM43、TRIM43B、TRIM45、TRIM46、TRIM47、TRIM48、TRIM49、TRIM49B、TRIM49C、T RIM49D1、TRIM5、TRIM50、TRIM51、TRIM52、TRIM54、TRIM55、TRIM56、TRIM58、TRIM59、TRIM6、TRIM60、TRIM61、TRIM62、 TRIM63、TRIM64、TRIM64B、TRIM64C、TRIM65、TRIM67、TRIM68、TRIM69、TRIM7、TRIM71、TRIM72、TRIM73、TRIM74、TRIM7 5P、TRIM77、TRIM8、TRIM9、TRIML1、TRIML2、TRIP12、TTC3、UBE3A、UBE3B、UBE3C、UBE3D、UBE4A、UBE4B、UBOX5、UBR1、UB R2、UBR3、UBR4、UBR5、UBR7、UHRF1、UHRF2、UNK、UNKL、VPS11、VPS18、VPS41、VPS8、WDR59、WDSUB1、WWP1、WWP2、CIAR、ZB TB12、ZFP91、ZFPL1、ZNF280A、ZNF341、ZNF511、ZNF521、ZNF598、ZNF645、ZNRF1、ZNRF2、ZNRF3、ZNRF4、ZSWIM2、ZXDC。、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0111] <h2 style=";text-align:left;direction:ltr"> Introducing improver without reagent circulation <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0112] CSF can be treated in a variety of ways (e.g., chronically, intermittently, etc.) according to various embodiments of the systems and methods of the present invention. For example, a static or substantially static improving agent that is completely implanted in a mammalian subject but outside the SAS can be presented to the CSF at a high flow rate. For example, untreated CSF may leave the SAS, may be improved by reagents outside the SAS, and then may return to the SAS. Typically, in order to transport CSF to the SAS and / or outside the body and return it to the SAS, this method may require the use of multiple catheters (and multiple insertion positions) and / or the use of multi-lumen catheters (and optionally only a single insertion position). CSF flow can occur naturally through active pumping or passive pumping. The advantages of this method include: it is less invasive to the SAS, is easy to enter the structure associated with the static improving agent, and it provides more space for the static improving agent and any pump element. This method involves the active circulation of CSF and the CSF fluid flow that needs to be carefully controlled.
[0113] In an alternative approach, the improver can be located on a structure in the SAS (e.g., a substrate, such as a locally fixed solid substrate) that can be collapsible or flexible and untreated CSF can circulate through the improver. In some applications, it may be desirable that the improver remain stationary or substantially stationary. In other applications, the improver can be intentionally actuated. The term substantially stationary means that the improver does not actively move, yet physiological CSF motion may cause fluctuations in the motion of the structure or in the structure.
[0114] Typically, CSF flow may occur naturally; however, in certain applications, active or passive pumping of CSF may be required to enhance improvement activity and efficiency. Depending on the circulation method implemented and / or the system or device used, CSF flow may remain entirely within the SAS. However, in some embodiments, CSF may be transported from one portion of the SAS to the outside of the SAS and returned to another portion of the SAS, which may require one or two or more catheter insertion locations.
[0115] In various embodiments, to reduce the possibility of infection, structures associated with the improving agent and / or system components (e.g., subcutaneous ports and reservoirs, active or passive pumps, etc.) can be implanted under the epidermis, inside or outside the SAS. Subcutaneous ports and reservoirs can be provided in the system to facilitate: CSF sampling; introduction or removal (e.g., firming) of substrates; introduction, removal or replenishment / renewal of improving agents; and / or administration of drugs (e.g., introduction and long-term maintenance) into the CSF (e.g., by bolus or continuously).
[0116] In the absence of active circulation of the reagent, the in situ improvement element can also reduce the concentration of the target biomolecule (e.g., DPR) in the CSF space. Assuming that the bulk flow is slow (e.g., about 0.5 mL / min), the improvement effect is mainly pulsatile flow, which may be due to the respiratory or cardiac cycle. Assuming that the active cross-sectional area of the enzyme device in the back-and-forth (i.e., pulsatile) flow is 10% of the flow cross-sectional area, and assuming that one collision or interaction between the biomolecule and the enzyme device will improve the biomolecule, the probability that the molecule will be improved (i.e., converted) after n passes is:
[0117] P(n)=1-(1-0.1) n .
[0118] Therefore, for P(n)>95%, n>ln(0.05) / ln(0.9)=28, or exposure time (t)>nx 3 seconds=85 seconds.
[0119] The method of local fluid flow through an element (e.g., cilia) that has been decorated with an improvement agent is schematically shown in Figures 1A to 1C In some embodiments, a structure or substrate 100 decorated with an improver (e.g., flexible or collapsible, firm) can be introduced into the SAS without circulating the improver. In some applications, the structure or substrate 100 can be implanted into the SAS through a catheter. CSF can selectively circulate (e.g., naturally, by actively pumping CSF, and / or by passively pumping CSF) through a stationary or substantially stationary improver. Therefore, the CSF flow rate can be equal to or exceed the natural CSF flow rate. Active and passive pumping and natural circulation can be performed completely within the SAS, or the CSF can enter and exit the SAS. The source and power for hydraulic or pneumatic actuation can be located outside the SAS. The surface and structure can be made of any suitable compliant and elastic biocompatible material, including polymers, elastomers, thermoplastic elastomers (TPE), etc. Although various embodiments are described in conjunction with hydraulic or pneumatic actuation surfaces, the structure can alternatively or additionally include a shape memory surface.
[0120] In some embodiments, the structure or substrate 100 may include an inner core 10a ( Figure 1A and 1C )、10b( Figure 1B ) and housing 20a( Figure 1C )、20b( Figure 1A and 1B), each of which has a reduced or contracted state (a) and an expanded or expanded state (b). A plurality of (e.g., hair-like or fibrous) cilia 25 may be integrally formed with the housing 20a, 20b or fixedly attached to the housing (e.g., the outer peripheral surface of the housing). Advantageously, in operation, different amounts of the improving agent 30 may be decorated or attached to the cilia 25 and / or each of the core and shell. The housing 20a, 20b may also include an inlet / outlet port 35, and a plurality of openings 40. The inlet / outlet port 35 is fluidly connected to a source (e.g., a hydraulic, pneumatic source, etc.) that is capable of selectively expanding and contracting the housing 20a, 20b, respectively, by introducing a fluid into the housing 20a, 20b and removing a fluid from the interior of the housing. The plurality of openings 40 are constructed and arranged to provide fluid communication between the inner peripheral surface and the outer peripheral surface of the housing 20a, 20b.
[0121] The cores 10a, 10b may also include inlet / outlet ports 45, which are also in fluid communication with a source (e.g., a hydraulic, pneumatic source, etc.) capable of selectively expanding and contracting the cores 10a, 10b by introducing fluid into and removing fluid from the interior of the cores 10a, 10b, respectively.
[0122] In the first step of the operation, from the rest state ( Figure 1C ), an expansion fluid 35 may be introduced (e.g., through an inlet / outlet port) into the contracted or reduced shell 20a to cause it to expand or expand and create a void space 15 ( Figure 1A ). The void space 15 contains the original or partially processed CSF. More specifically, as the contracted or reduced shell 20a expands or expands, the CSF flows into the void space 15 through the openings 40 in the expanded shell 20b and through the cilia 25 decorated with the improving agent 30, increasing the possibility that the improving agent 30 will enzymatically digest the biomolecules in the CSF.
[0123] In the next step ( Figure 1B ), an expansion fluid (e.g., via inlet / outlet port 45) can be introduced into the contracted or reduced inner core 10a to cause it to expand or expand. Advantageously, as the contracted or reduced inner core 10a expands, the initial or partially treated CSF in the void space 15 is forced through the openings 40 in the expanded outer shell 20b. As the CSF leaves the openings 40, the untreated CSF flows through the cilia 25 decorated with the improving agent 30, increasing the likelihood that the improving agent 30 will enzymatically digest the biomolecules within the CSF.
[0124] In the next step ( Figure 1C), the expansion fluid previously introduced into the expanded core 10b and the expanded shell 20b can be discharged from the expanded core 10b and the expanded shell 20b, causing each to shrink or contract to a static state, such as the contracted or contracted core 10a and the contracted or contracted shell 20a. Advantageously, as the expanded shell 20b shrinks or contracts, CSF flows through the cilia 25 decorated with the improving agent 30, increasing the possibility that the improving agent 30 enzymatically digests the biomolecules in the CSF.
[0125] Another embodiment of the method and system for local fluid flow through the element (such as cilia) decorated with an improver is shown in Figure 2A to Figure 2C. In some embodiments, (such as, flexible or collapsible, firm) structure or substrate 200 can be introduced into SAS without circulating improver. In some applications, structure or substrate 200 can be implanted into SAS by catheter. CSF can selectively circulate (such as, naturally, by active pumping CSF, and / or by passive pumping CSF) through static or substantially static improver. Active and passive pumping and natural circulation can be carried out completely in SAS, or CSF can enter and exit SAS. The source and power for hydraulic or pneumatic actuation can be located outside SAS. Although various embodiments of the present invention are described in conjunction with hydraulic or pneumatic actuation surfaces, structure can alternatively or additionally include shape memory surface. Passive pumping can include peristaltic pump or other forward displacement pump or can use pressure changes in vivo to provide power for CSF circulation in specific system. In some embodiments, the structure or substrate 200 can include an integral bistable substrate 205a, 205b having a plurality of appendages 210 that form a plurality of inward 210a and outward 210b structures between structural bodies 215. As shown in FIG2B , a plurality of cilia 220 can be integral with or fixedly attached to the peripheral surface of the appendages 210, thereby projecting from the peripheral surface of the outward appendages 210b and to the peripheral surface of each inward appendage 210a and to the structural body 215 to cover the pockets formed thereby. Advantageously, in operation, different amounts of an improving agent can be decorated or attached to each of the appendages 210 and the body 215, including the cilia 220.
[0126] The structure or substrate 200 may also include an inlet / outlet port 225 to provide fluid communication between the bistable substrates 205a, 205b and a source (e.g., hydraulic, pneumatic, etc.) capable of selectively expanding and contracting the bistable substrates 205a, 205b by introducing fluid into and removing fluid from the interior of the substrates 205a, 205b, respectively.
[0127] From the bistable substrate 205a in a deflated or substantially deflated resting state (FIG. 2A), in a first step (FIG. 2C), an expansion fluid may be introduced (e.g., via the inlet / outlet port 225) into the bistable substrate 205a, causing it to swell or expand 230. Advantageously, as the bistable substrate 205b and the appendages 210b expand 230, the expanded substrate 205b and the expanded appendages 210b mix the CSF, exposing a greater volume of CSF to the cilia 220 decorated with the improving agent (FIG. 2B), increasing the likelihood that the improving agent will enzymatically digest biomolecules within the CSF.
[0128] In the next step, the fluid previously introduced to expand the substrate 205b and the appendages 210b can be expelled, causing the substrate 205b to shrink or contract 235 to a stationary state (FIG. 2A). Again, as the bistable substrate 205a and the appendages 210a contract 235, the contracting substrate 205a and the contracting appendages 210a mix the CSF, exposing a larger volume of CSF to the cilia 220 coated with the improving agent, increasing the likelihood that the improving agent will enzymatically digest biomolecules within the CSF. Thus, multiple cycles of expansion and contraction of the structure or substrate 200 produce a mixing motion of the CSF, further increasing the interaction between the CSF and the cilia 220 coated with the improving agent, and the likelihood that the improving agent will enzymatically digest biomolecules within the CSF.
[0129] Another embodiment of a method for localized fluid flow through an element that has been decorated with a modification agent (e.g., a window) is shown in Figure 3 In some embodiments, (e.g., flexible or collapsible, firm) structure or substrate 300 can be introduced into SAS without circulation improver. In some applications, structure 300 can be implanted into SAS through a catheter. CSF can selectively circulate (e.g., naturally, by actively pumping CSF, and / or by passively pumping CSF) through a stationary or substantially stationary improver. Therefore, CSF flow rate can be equal to or exceed natural CSF flow rate. Active and passive pumping and natural circulation can be performed completely within SAS, or CSF can enter and exit SAS. The source and power for hydraulic or pneumatic actuation can be located outside SAS. Surfaces and structures can be made of any suitable compliant and elastic biocompatible material, including polymers, elastomers, thermoplastic elastomers (TPE), etc. Although various embodiments and implementations of the present invention are described in conjunction with hydraulic or pneumatic actuation surfaces, the structure can alternatively or additionally include a shape memory surface.
[0130] In some embodiments, the structure of substrate 300 may include substrate 305 having a plurality of appendages (ie, fenestrations 310) and gaps 315. Advantageously, different amounts of modifier 350 may decorate or attach to each fenestration 310.
[0131] In operation, after the substrate 305 has been introduced into the SAS, the substrate 305 can be alternately expanded and contracted as described above. Multiple expansion and contraction cycles of the structure 300 produce mixed motions of the CSF, further increasing the interaction between the CSF and the improver 350 decorated on the window 310, and the possibility of the improver enzyme digesting the biomolecules in the CSF. Alternatively, or in addition, the substrate 305 can vibrate back and forth or slowly rotate / twist to produce micromotion. The back and forth rotation or vibratory micromotion can also increase the interaction between the CSF and the improver 350 decorated on the window 310, and the possibility of the improver enzyme digesting the biomolecules in the CSF. Advantageously, the structure 300 can be made of a single material and / or a single piece of material, thereby reducing the risk of mechanical failure.
[0132] Another system or device and method for local fluid flow through an element (e.g., extensible fiber) decorated with an improver is shown in Figures 4A and 4B. In some applications, structure or substrate 400 can be implanted in SAS by a catheter. CSF can selectively circulate (e.g., naturally, by active pumping CSF, and / or by passive pumping CSF) through a static or substantially static improver. Therefore, CSF flow can be at or exceed natural CSF flow level (e.g., flow rate). Active and passive pumping and natural circulation can be carried out completely in SAS, or CSF can enter and exit SAS. The source and power for hydraulic or pneumatic actuation can be located outside SAS. Surface and structure can be made of any suitable compliant and resilient biocompatible material, including polymers, elastomers, thermoplastic elastomers (TPE), etc. Although some embodiments or applications of the present invention are described in conjunction with hydraulic or pneumatic actuation surfaces, the structure can alternatively or additionally include shape memory surfaces.
[0133] In some embodiments, the structure 400 may include a (e.g., tubular) structure or sleeve (e.g., catheter 405) containing a plurality of hair-like fibers 410a, 410b (e.g., brush-like fibers). Advantageously, the fibers 410a, 410b are retractable and expandable such that when the catheter 405 is introduced into or withdrawn from the SAS, the fibers 410a may remain in a retracted state (FIG. 4A); however, when subjected to CSF flow (FIG. 4B), the retracted fibers 410a may expand and extend from the catheter 405 into the SAS. Optionally or alternatively, the structure or sleeve 400 may also be vibrated or rotated / twisted to generate micromotion to promote local CSF movement through the extended fibers 410b.
[0134] Advantageously, different amounts of improving agent 415 may be decorated or attached to each of the fibers 410a, 410b, such that when the fiber 410b extends into the CSF space, the extended fiber 410b provides a large volume for interacting with the CSF, increasing the interaction between the CSF and the improving agent 415, and the likelihood that the improving agent 415 enzymatically digests biomolecules within the CSF.
[0135] Although the above embodiments have been described as having the corresponding structures completely implanted within the SAS, it will be appreciated by those skilled in the art that some portions of the implanted structures may be within the SAS, while other portions may be implanted within the body of a mammalian subject, but outside the SAS. Such an arrangement would require CSF to circulate from the SAS, through the structures implanted outside the SAS, and then back to the SAS. The source and power for hydraulic or pneumatic actuation may be located outside the SAS.
[0136] Another method of local fluid flow using a structure that has been decorated with an improving agent is shown in Figure 5 In some embodiments, the specific structure 505 can be introduced (i.e., completely implanted) into the SAS (e.g., in the cerebral aqueduct, near the fourth ventricle, etc.) without the need for a circulation improving agent. Instead, the CSF can be selectively circulated naturally by active pumping of the CSF and / or by passive pumping of the CSF in the presence of an improving agent. Active and passive pumping of the CSF and the natural circulation of the CSF can be performed entirely within the SAS, or the CSF can enter and exit the SAS.
[0137] like Figure 5 As shown, in some embodiments, structure 500 can include a support 505 having an inner peripheral surface to which the improving agent can be coated, decorated, or otherwise applied. Placing support 505 in a location within the SAS that experiences relatively high CSF flow (e.g., in the cerebral aqueduct, near the fourth ventricle, etc.) increases the interaction between the CSF and the improving agent, and the likelihood that the improving agent will enzymatically digest biomolecules within the CSF.
[0138] In another embodiment, the structure 500 may include a sheet (e.g., planar, wavy, spiral, etc.) onto which the modifying agent may be coated or otherwise applied. Placing the coated sheet at a location in the SAS that experiences relatively high CSF flow (e.g., over the motor cortex, in the SAS pool, etc.) increases the likelihood that the modifying agent will enzymatically digest biomolecules within the CSF.
[0139] Enzymatic digestion and size filtration
[0140] refer to Figure 6, shows an exemplary embodiment of a system 600 that combines enzymatic digestion (ie, using an enzyme digester) and size filtration. In some applications, the system 600 may include a plurality of size-charge filters 605a, 605b in combination with a structure containing an improvement agent 610 (eg, an enzyme digester).
[0141] Figure 6 The illustrated loop flow embodiment utilizes countercurrent exchange.In operation, untreated CSF having the highest concentrations of small components 615, large non-toxic biomolecules 620, and large biomolecules 625a can flow into system 600 in a first direction (eg, to the right) away from the highest concentrations.
[0142] After the high concentration, untreated CSF enters the system 600, it encounters a first size charge filter (e.g., a porous wall) 605a, which separates the high concentration, untreated CSF traveling in a first direction from the low concentration, filtered and treated CSF traveling in a second, opposite direction. The size of the openings in the first porous wall 605a can be selected to allow small components 615 to pass through the filter, which occurs when the small components 615 generally flow from a higher concentration to a lower concentration. As the small components 615 filter through the first porous wall 605a, some of the smaller components 615 are separated (i.e., filtered out) from the large non-toxic biomolecules 620 and the large biomolecules 625a. The filtered small components 615 can flow out of the system 600 with the treated CSF.
[0143] In the next step, the filtered CSF may encounter or contact an improving agent 610 (e.g., in an enzymatic digester). Although the improving agent 610 may be selected so as to have little or no effect on the remainder of the small fraction 615 or on the large non-toxic biomolecules 620, by design, the agent 610 improves (e.g., enzymatically digests) the large toxic biomolecules 625a, resulting in a reduction in the size of these improved biomolecules 625b.
[0144] As the treated CSF continues to flow to the right, out of the enzyme digester and the improvement agent 610, the treated CSF encounters a second size charge filter (e.g., a porous wall) 605b to separate the improved biomolecules 625b from the large non-toxic biomolecules 620 that are not affected by the enzyme digestion. The size of the openings in the second porous wall 605b can be selected to allow the improved biomolecules 625b to pass through the filter 605b, which occurs when the improved biomolecules 625b tend to flow from a higher concentration to a lower concentration. Some small components 615 can also be filtered through the second porous wall 605b. Those small components 615 and improved biomolecules 625b that are filtered out by the second porous wall 605b can be discharged (e.g., as waste) to a capsule or other location. The treated CSF containing some small components 615 and large non-toxic biomolecules 620 can then leave the system 600 to the left (e.g., in a countercurrent flow mode).
[0145] refer to Fig.17 Another filtration system depicted in , showing a schematic diagram of an embodiment of a tangential flow filtration segment combined with an enzyme cartridge 1707. System 1700 shows a fluid (e.g., CSF) extracted from the patient's subarachnoid space (SAS) through a catheter and circulated to a filtration subsystem 1700. The fluid at this time contains a variety of potential components, including cells, tissue fragments, immunoglobulins, target toxic proteins (e.g., TDP-43, dipeptide repeat proteins (DRPs), phosphorylated tau, etc.), albumin, glucose, ions, and other species. CSF enters the first section 1701 of tangential flow filtration (TFF), where CSF is separated into a retentate 1702 and a permeate 1703 flow by a membrane with a high molecular weight cutoff (MWCO). For example, in the first section, a MWCO of approximately 55kDa will pass cells and albumin, but filter smaller proteins, glucose, and ions. The permeate 1703 can then be transmitted to a second section TFF 1704 with a lower MWCO (e.g., about 3kDa). Second section 1704 filters smaller species, such as ions and glucose, as permeate 1705, while larger proteins are retained as retentate 1706. Retentate 1706 can then be transferred to enzyme cartridge 1707. In this cartridge 1707, enzyme (e.g., trypsin) digests the target protein and allows the fragment to pass through output 1708. Advantageously, in order to increase the retention time and therefore increase the exposure of retentate 1706 to the enzyme (e.g., trypsin) disposed on and / or decorated on cartridge 1707, the flow of CSF can follow a dual-flow mode through cartridge 1707, i.e., the mobile phase can flow through the stationary phase in a single or repeated bidirectional manner. In this mode, CSF is sucked in, then discharged in one or more cycles, and then delivered to the output. In this variation, the output port of cartridge 1707 can be identical to the input port of cartridge 1707.
[0146] The output 1708 of the enzyme cartridge 1707 may then be passed to a third TFF stage 1709 having a MWCO sufficient to separate the digested fragments from the whole protein.
[0147] The digested fragments, which may include self-digested trypsin, may then be passed to waste 1710. The retentate stream 1712 may contain undigested intact target protein and enzymes separated from the substrate in 1707. This stream may then be passed to a second cartridge 1711 containing a "getter," such as immobilized Alpha-1 antitrypsin, which serves to capture any free-floating trypsin released from the first cartridge 1707. More specifically, to prevent or minimize loose enzymes previously disposed in and / or decorated on the first cartridge 1707 from reaching the SAS via the treated CSF, the getter may be located downstream of the first cartridge 1707 such that the getter catches or captures loose or free enzymes contained in the output stream 1712. In some embodiments, when the enzyme is trypsin, a suitable absorbent material may be Alpha-1 antitrypsin AAT; while for proteases, more generally phthalamide, benzamidine (e.g., benzamidine Sepharose 4Fast Flow (High Sub), GE Healthcare Lifescience, Cytiva), etc. may be used. In some variations, the aspirating material may be fixed on a surface, such as a lumen, beads, fine mesh, cilia, fiber structure, etc. Finally, the output stream 1712 is merged with the other streams 1702 and 1705 into stream 1713, which is reintroduced and recirculated into the patient. The MWCO of the segment may be adjusted to best suit the desired target species.
[0148] Advantageously, due to the nature of the tangential flow filtration stage, the filtration system will be less prone to clogging with tissue and cell debris. In addition, this configuration removes digested fragments of toxic proteins from the enzyme cartridge 1707. In addition, the second cartridge captures any enzymes separated from the first cartridge. Finally, the cartridge has a cleaner feed stream due to the earlier TFF stage.
[0149] Fluid Flow and Enhanced Fluid Flow
[0150] Although in some embodiments of the systems, methods, and devices described herein, it is acceptable to allow natural CSF flow, in other embodiments, it may be desirable to use active and / or passive pumping techniques to control CSF flow. Pumping techniques may include pumps, valves, actuators, and combinations thereof. For example, pumps may include peristaltic pumps, rotary vane pumps, Archimedean screws, air bags, inflatable bags, hydraulic bags, piston pumps, electric pumps, passive pumps, automatic pumps, valveless pumps, bidirectional pumps, and combinations thereof. Valves may include one-way valves, mitral valves, tricuspid valves, ruby valves, and combinations thereof.
[0151] Improvement techniques involving the use of an improver (as opposed to the use of a therapeutic system) may require active (or positive) implementation of flow from one location (e.g., within or from outside the SAS) to another location within or outside the SAS. In practice, by providing an improver with high CSF circulation, the interaction between the CSF and the improver can be increased, which increases the likelihood that the improver enzymes will digest biomolecules within the CSF. When implementing fluid flow, the CSF can circulate through a stationary or substantially stationary structure decorated or coated with the improver, the structure decorated or coated with the improver can circulate through the CSF, or the CSF and the structure decorated or coated with the improver can both circulate through each other.
[0152] In the case of CSF circulation, such movement may occur as part of the natural flow of the fluid, or the natural flow may be actively or passively augmented. Such active or passive augmentation (i.e., pumping) may occur simultaneously, periodically, sequentially, etc. In addition, as described above, the CSF may be completely circulated within the SAS, or, alternatively, after the CSF has circulated through the modifying agent, the CSF may be transported out of the SAS but later reintroduced into the SAS.
[0153] As previously discussed, pressure changes and / or volume changes associated with naturally flowing fluids and / or artificially increased flowing fluids in a SAS should be regulated to avoid or minimize effects that may result in spinal headaches or even death to a subject. Thus, when fluids are removed from a SAS and / or reintroduced into a SAS, pressure transients may depend, at least in part, on the duty cycle and flow rate of the process involved.
[0154] Although turbulent mixing of the CSF may be desirable in some applications, in general, high levels of fluid motion within the CSF space may also cause discomfort to the subject. Therefore, fluid flow—whether actively pumped within the SAS, passively pumped within the SAS, or pumped from the SAS and reintroduced into the SAS—should be controlled to avoid excessive or unnecessary mixing of the fluid. Indeed, while some mixing is desirable and beneficial, excessive or unnecessary mixing is generally not preferred.
[0155] The source of actuation and power supply associated with the system components may be located external to the SAS. The power required for the pump can be estimated as follows:
[0156] P h(kW) =qρg z / (3.6x 10 6 ),
[0157] in:
[0158] P h(kW) = hydraulic power (kW),
[0159] q = flow rate (m3 / h),
[0160] ρ = fluid density (kg / m 3 ),
[0161] g = gravity (9.81 m / s 2 ),and
[0162] z = head difference (m).
[0163] The required flow rate (q) is about 20 mL / h, or about 20 x 10 -6 m 3 / h. The density of CSF (ρ) is about 1.00059x10 3 kg / m 3 The average spine length (z) is about 0.5 m. If the pump efficiency is 0.6, then P = 27 μW.
[0164] A lithium thionyl chloride battery (e.g., the LTC-EP-200014 battery manufactured by EaglePicher of St. Louis, Missouri) has a capacity of 8 Ah. Therefore, this battery can in principle operate at about 8 Ah / (30 μW / 3 V) = 8 x 10 5 h. System losses will reduce this time value, while the natural flow of CSF will reduce the demand on the pump, if not completely relieve it.
[0165] refer to Fig. 7A and 7B , shows an exemplary integrated, hydraulically activated peristaltic pump 700 that can be implanted within a SAS or elsewhere within a subject's body. In some embodiments, the pump 700 can include a plurality of chambers 705, 710 in which a pair of opposing selectively expandable bladders 715a, 715b are located. Fig. 7A The two-chamber pump 700 shown includes a front chamber 705 and a rear chamber 710, but a greater number of chambers is possible. Upstream and downstream of each chamber 705, 710 may be a mitral valve 720a, 720b, 720c, which may be constructed and arranged near a sac 715a, 715b. Advantageously, the one-way nature of the mitral valve 720a, 720b, 720c prevents backflow into the pump 700 or the previous chamber 705, 710.
[0166] Actuating the balloons 715a, 715b sequentially causes fluid (e.g., CSF or ISF) to enter the anterior chamber 705 through the first mitral valve 720a, for example, by alternately inflating and deflating the balloons 715a, 715b. For example, when the balloon 715a in the anterior chamber 705 contracts or deflates from a previously inflated or expanded state, the contraction of the balloon 715a causes the pressure within the anterior chamber 705 to decrease, drawing fluid from outside the anterior chamber 705 into the anterior chamber 705 through the first mitral valve 720a. When the balloon 715b in the posterior chamber 710 simultaneously contracts or deflates from a previously inflated or expanded state, the contraction of the balloon 715b causes the pressure within the posterior chamber 710 to decrease, drawing fluid from the anterior chamber 705 into the posterior chamber 710 through the second mitral valve 720b. In the next cycle, when the balloon 715b in the posterior chamber 710 expands from the previously deflated or contracted state, the expansion of the balloon 715b forces fluid from the posterior chamber 710 to flow out of the posterior chamber 710 via the third mitral valve 720c.
[0167] In some embodiments, it may be desirable to have a passive pump structure that is fully implantable in a SAS (e.g., skull or spine). Figures 8A to 8C , shows a structure 800 with a passive pump 805 that uses the normal pressure fluctuations of the CSF itself to circulate fluid through the structure 800. In some variations, the structure 800 can also be connected to an implanted subcutaneous adapter, which will facilitate the introduction, maintenance, and removal of the structure 800.
[0168] In some applications, the structure 800 may include a cartridge 810 (eg, a catheter body) having a first opening and a second opening, wherein a first one-way valve 815a and a second one-way valve 815b are operably disposed at the first opening and the second opening. Each opening and one-way valve 815a, 815b is in fluid communication with a CSF space 820.
[0169] The tube 810 can be rigid or flexible. In some variations, the rigid tube 810 can include multiple metal spiral rings or spiral structures, which can be configured to support a radially unobstructed lumen. Although rigidity is desirable for promoting fluid to flow into the tube 810, the tube 810 should maintain enough flexibility to fit the anatomical contour in the SAS 820. In other variations, the tube can be flexible (e.g., elastic), so that along with the (e.g., compressed) shape recovery of the tube 810, the recovery of the shape can drive the fluid to flow into the tube 810 from the SAS.
[0170] In some embodiments, a passive pump 805 (eg, an air or automatic bladder) can be located within the cartridge 810. An improving agent 825 can be coated on the inner surface of the cartridge 810.
[0171] Although structure 800 will be described as having been fully implanted in the spinal SAS, it will be appreciated by those of ordinary skill in the art that it may also be implanted in the cranial SAS. For example, in one embodiment, structure 800 may be implanted in the spinal SAS, extending significantly in the cranial and caudal direction, so that CSF circulates and improves between the brainstem region and the lumbar region. Advantageously, such a position causes mixing with brain SAS fluid as well as spinal SAS fluid. In another embodiment, structure 800 may be implanted in the cranial SAS so as to operably induce flow between locations therein (e.g., between the cerebral cisterns and the frontal lobes, between the two lateral hemispheres, etc.).
[0172] Although the operation of the passive pump 805 will be described in multiple stages, in practice, the sequence of steps should be viewed as a more continuous process. Fig. 8A ), the passive pump 805 within the cartridge 810 may be in an expanded state such that the pressure (P') within 830 of the passive pump 805 is equal to the (eg, relatively low) pressure (P) in the spinal space 820. Figure 8B As shown, as the pressure (P) in the spinal space increases, the increased external pressure (P) compresses the passive pump 805, causing it to deflate. As the passive pump 805 deflates within the barrel 810, the pressure (P') in the barrel decreases (i.e., is lower than the external pressure (P)), causing fluid to flow into the barrel 810 through the first one-way valve 815a, while the second one-way valve 815b remains closed. Advantageously, when untreated CSF enters the barrel 810 via the first one-way valve 815a, the untreated CSF can be exposed to the surface area decorated with the improving agent 825, increasing the possibility that the improving agent 825 will enzymatically digest the biomolecules within the CSF.
[0173] When the pressure (P) in the SAS decreases again, the passive pump 805 expands again, forcing the processed CSF out of the cartridge 810 through the second one-way valve 815b. Because the expansion of the passive pump 805 creates an overpressure in the cartridge 810, the first one-way valve 815a remains closed.
[0174] In another embodiment, the pump 805 can be connected to an external source of pressure variation, an active gas reservoir or pump, or another location in the anatomy where pressure varies regularly (e.g., the abdominal or pleural cavity). This external source of pressure variation then drives the balloon actuator in the pump.
[0175] exist Fig.8D In yet another embodiment depicted in FIG, device 800' is provided with a porous separator 850 that separates the modifying agent 825 from the CSF circulating through the lumen 830 of the device. Advantageously, this configuration presents a significantly larger surface to the CSF than the modifying agent that may be decorated on the inner surface of cartridge 810.
[0176] like Fig.8D As shown, this embodiment includes a barrel 810' that includes a porous wall (or separator) 850. The porous wall 850 separates the main lumen 830 from the separate lumen 835. In some variations, the porous wall 850 can be concentric and coaxial with the barrel 810. However, in some applications, the porous wall 850 can be eccentric relative to the barrel 810.
[0177] In some embodiments, an improving agent 825 may be provided and confined within a separate lumen 835, while CSF circulates through the main lumen 830. As CSF flows through the main lumen 830, untreated or partially treated CSF has the opportunity to interact with the improving agent 825, which may be decorated, for example, on a plurality of beads. Advantageously, the size of the holes in the porous wall 850 is determined to retain and confine the beads coated with the improving agent 825 within a separate lumen 835 while allowing biomolecules to pass through the porous spacer 850. A pair of one-way valves 815a, 815b are formed at opposite ends of the barrel 810, in fluid communication with the CSF space. A passive pump (e.g., an automatic pump) 805 may be located within the main lumen 830.
[0178] The operation of 800 ′ is similar to that of 800 , except that the modifier 825 is isolated behind a porous wall 850 .
[0179] refer to Fig. 8E , a laboratory-scale implementation of an open-ended balloon catheter automatic pump 800" for continuous extracorporeal use is shown to illustrate the principle of the automatic pump 800". In some embodiments, the automatic pump 800" includes an expandable balloon 860 disposed within the lumen of a rigid or substantially rigid catheter 855. In some variations, a barrel 865 may also be disposed within the lumen of the catheter 855. The improving agent may be disposed within the barrel 865. Alternatively, the improving agent may be adhered to the inner surface of the barrel 865.
[0180] The first check valve 870a can be arranged upstream of the balloon catheter 855, and the second check valve 870b can be arranged downstream of the balloon catheter 855. A T-shaped connector 875 can be arranged upstream of the balloon catheter 855 but downstream of the first check valve 870a. A conduit 880 providing fluid communication between a pressure source 885 and the balloon 860 is arranged in the T-shaped connector 875. The pressure source 885 is an external source of pressure changes, an active gas reservoir or a pump, which is constructed and arranged to selectively or cyclically inflate and deflate the balloon 860 to move CSF through the automatic pump 800".
[0181] In operation, the upstream end 890a of the automatic pump 800" can be inserted into a first location of a mammalian subject to provide fluid communication with the CSF space, and the downstream end 890b of the automatic pump 800" can be inserted into a second location of the mammalian subject to provide fluid communication with the CSF space 820. In some applications, each inflation and deflation cycle of the balloon 860 draws in and out a volume of CSF, which is then exposed to an improving agent contained in or adhered to a cylinder 865 disposed within the catheter 855 or in fluid communication with the catheter. More specifically, as the balloon 860 is deflated (e.g., by the pressure source 885), a pressure differential is created between the lumen of the catheter 855 and the exterior. The pressure differential causes the first (e.g., upstream) check valve 870a to open and the second (e.g., downstream) check valve 870b to remain closed, such that fluid is drawn into the catheter 855 from the upstream end 890a. Once the pressures are balanced, both check valves 890a, 890b are closed. Next, as the balloon 860 is inflated (e.g., by the pressure source 885), a pressure differential is created between the lumen and the exterior of the catheter 855. This pressure differential causes the second (e.g., downstream) check valve 870b to open, while the first (e.g., upstream) check valve 870a remains closed, allowing fluid to be drained from the catheter 855 and the cartridge 865 disposed within the catheter 855 and toward the downstream end 890b.
[0182] refer to Figure 8F , a laboratory-scale implementation of an automatic pump 800'' of a closed-end balloon catheter for intermittent extracorporeal use is shown to illustrate the principle of the automatic pump 800''. In some embodiments, the automatic pump 800'' includes an expandable balloon 860 disposed within the lumen of a rigid or substantially rigid catheter 855. In some variations, a barrel 865 may also be disposed within the lumen of the catheter 855. The improving agent may be disposed within the barrel 865 or in fluid communication with the barrel. Alternatively, the improving agent may be adhered to the inner surface of the barrel 865. In operation, after a certain volume of fluid (i.e., a batch) is removed from a patient, the volume of fluid may be contained in a closed loop, wherein, due to the dual flow capability, the removed volume of fluid may be introduced and reintroduced, back and forth or repeatedly sequentially through the barrel 865 to increase the residence time and exposure of the removed fluid to the improving agent within the barrel 865. Once the processing of the batch is completed, the processed volume of fluid, i.e., the batch, may then be returned to the patient from the closed loop. Another batch of fluid may then be removed from the patient and the batch processing process repeated.
[0183] More specifically, the first check valve 870a can be disposed upstream of the balloon catheter 855, while the second check valve 870b can be disposed downstream of the balloon catheter 855. A T-connector 875 can be disposed upstream of the balloon catheter 855 but downstream of the first check valve 870a. A conduit 880 providing fluid communication between a pressure source 885 and the balloon 860 is disposed in the T-connector 875. The pressure source 885 is an external source of pressure variation, an active gas reservoir or a pump, which is constructed and arranged to selectively or cyclically inflate and deflate the balloon 860 to move CSF through the automatic pump 800''.
[0184] In operation, the upstream end 890a and the downstream end 890b of the automatic pump 800" are physically connected at the joint 890c. In some applications, each inflation and deflation cycle of the balloon 860 draws in and discharges a certain volume of CSF, which is then exposed to the improving agent contained in or adhered to the cylinder 865 disposed within the lumen of the catheter 855. More specifically, as the balloon 860 is deflated (e.g., by the pressure source 885), a pressure differential is generated between the lumen of the catheter 855 and the outside. This pressure differential causes the first (e.g., upstream) check valve 870a to open and And the second (e.g., downstream) check valve 870b remains closed, so that fluid is drawn into the lumen of the catheter 855 from the upstream end 890a. Once the pressures are balanced, both check valves 870a and 870b are closed. Next, as the balloon 860 expands (e.g., by the pressure source 885), a pressure differential is generated between the lumen of the catheter 855 and the exterior. This pressure differential causes the second (e.g., downstream) check valve 870b to open, while the first (e.g., upstream) check valve 870a remains closed, so that fluid is drained from the catheter 855 and discharged toward the downstream end 890b.
[0185] The open-ended automated pump 800" may be modified with a closed loop closed-ended automated pump 800"' with appropriate valves to obtain a batch of fluid from a patient, isolate the patient, process the fluid, and then return the processed batch of fluid to the patient.
[0186] refer to Fig.13 , a schematic diagram of a laboratory scale embodiment of an automatic pump 1300 in a pressurized chamber 1305 is shown. In some embodiments, CSF can be introduced into an arrangement including a (e.g., flexible tube) cartridge 1310 containing an improving agent. A first conduit 1315 provides fluid communication from a position outside the chamber 1305 to a first end of the cartridge 1310 and a second conduit provides fluid communication from a second end of the cartridge 1310 to a position outside the chamber 1305. A first check valve 1320a can be disposed upstream of the cartridge 1310 at the first end and a second check valve 1320b can be disposed downstream of the cartridge 1310 at the second end. The cartridge 1310 can be immersed in a liquid contained in the pressurized chamber 1305.
[0187] A pressure generating source (e.g., an air compressor, a pressure differential device, etc.) 1325 capable of generating a pressure change may be placed in fluid communication with the internal pressurized space of the pressurized chamber 1305. A pressure relief valve 1330 for releasing pressure may also be placed in fluid communication with the pressurized space of the pressurized chamber 1305.
[0188] In operation, a volume of CSF can be introduced into the barrel 1310 via a suitable fluid connection via the first conduit 1315. The pressure generating source 1325 increases the pressure of the gas (e.g., air) contained in the pressurized chamber 1305, and the pressure relief valve 1330 reduces the gas pressure in the pressurized chamber 1305 when it is opened. The increase in gas pressure causes an increase in liquid (e.g., water) pressure, which collapses the flexible barrel 1310. The collapsed barrel 1310 drives a volume of CSF out of the barrel 1310 via the second check valve 1320b and the second conduit. When the pressurized gas is discharged through the pressure relief valve 1330, the liquid (e.g., water) pressure decreases, causing the flexible barrel 1310 to expand. The expanded barrel 1310 draws a new volume of CSF into the barrel 1310 through the first check valve 1320a and the first conduit 1315. The cycle can then be repeated.
[0189] refer to Figures 14A-14C , shows an embodiment of an automatic pump 1400 having a balloon 1405 enclosed within the lumen of a barrel 1410. A first check valve 1420a may be disposed upstream of the barrel 1410 and the balloon 1405, while a second check valve 1420b may be disposed downstream of the barrel 1410 and the balloon 1405. Changes in fluid pressure within the canister cause the balloon 1405 to expand and swell 1405b ( Fig.14A and 14C ) or collapse or shrink 1405a( Fig. 14B ). In clinical operation, either end of the automatic pump 1400 can be set at two different locations within the SAS.
[0190] In clinical operation, CSF fills the automatic pump 1400 and further surrounds the device. At lower ambient CSF pressure, the balloon 1405b expands or inflates ( Fig. 14C ). Under higher ambient CSF pressure, balloon 1405a collapses or deflates ( Fig. 14B ). As the balloon expands 1405b, the first check valve 1420a closes and the second check valve opens, causing fluid to be discharged from the cylinder 1410. When the balloon deflates 1405a, the first check valve 1420a opens and the second check valve closes, causing fluid to be drawn into the cylinder 1410.
[0191] As a result, as the fluid pressure in the SAS space alternately increases and decreases, the balloon 1405 will expand 1405b or contract 1405a. This repeated expansion and contraction of the balloon 1405 causes the fluid to flow through the check valves 1420a, 1420b in one direction, thereby realizing the CSF pump 1400 driven by internal pressure fluctuations. In some applications, the improver can be arranged in the inner cavity of the barrel 1410. Alternatively, in other applications, the improver can be arranged in the automatic pump 1400 or in series with the automatic pump 1400 fluid.
[0192] refer to Figures 9A to 9C , a fully implantable structure 900 for active (e.g., hydraulic, pneumatic, etc.) pumping of CSF is shown. Although the structure will be described for use in conjunction with the previously described structures 100, 200, 300, 400, 500, 600, 700, 800, it will be appreciated by those skilled in the art that the inner surface of the structure 900 may also be decorated with an improving agent, such that when the untreated or partially treated CSF is actively pumped in one direction or another, the untreated or partially treated CSF may be exposed to the surface area decorated with the improving agent, increasing the likelihood that the improving agent will enzymatically digest the biomolecules within the CSF.
[0193] The operating principle of the structure 900 uses pulsating flow actuated hydraulically, pneumatically (e.g., using helium), etc. In some embodiments, the structure 900 may include a barrel 905 containing a pair of bladders 910, 915 disposed at opposite ends of the barrel 905. Although this embodiment uses a barrel 905, it will be appreciated by those skilled in the art that a solid barrel is not required, and in some variations, the pair of bladders 910, 915 may alternatively be disposed at two locations along with the SAS itself.
[0194] From a neutral or stationary state ( Fig. 9B ), one of the bladders may be inflated while the other bladder is deflated simultaneously. To maintain a no net volume change condition within the SAS, the inflated bladder may be deflated while the deflated bladder is inflated. Preferably, the rate and extent of inflation / deflation should not result in pressure or volume changes that exceed or significantly exceed physiological variations, nor should it result in undesirable or excessive turbulence. As previously mentioned, in some cases, a certain degree of turbulence is desirable, such as mixing treated and untreated / partially treated CSF.
[0195] In order to generate a rightward pressure gradient from a neutral or intermediate state ( Fig. 9A), the first bladder 910b can be (e.g., hydraulically, pneumatically, etc.) expanded 910a, while the second bladder 915b can be deflated 915a. This creates a pressure gradient from the expanded bladder 910a to the deflated bladder 915a, causing fluid to flow from the expanded bladder 910a to the deflated bladder 915a. Each of the expanded bladder 910a and the deflated bladder 915a can then return to a resting or neutral state ( Fig. 9B ), the balloon 910a that needs to be expanded is deflated to the intermediate pressure 910b and the deflated balloon 915a is inflated to the intermediate pressure 915b.
[0196] In order to generate a leftward ( Fig. 9C ), the second bladder 915b can be expanded 915c (e.g., hydraulically, pneumatically, etc.), and the first bladder 910a can be deflated 910c. This creates a pressure gradient from the expanded bladder 915c to the deflated bladder 910c, causing fluid to flow from the expanded bladder 915c to the deflated bladder 910c. Each of the expanded bladder 915c and the deflated bladder 910c can then return to a resting or neutral state ( Fig. 9B ), the balloon 915c that needs to be expanded is deflated to the intermediate pressure 915b and the deflated balloon 910c is inflated to the intermediate pressure 910b.
[0197] By cycling the structure 900, CSF flow can be actuated and circulated within the SAS in a pulsatile manner without introducing or withdrawing fluid from the space. The phase and / or amplitude of the actuated CSF flow can enhance or attenuate an existing pulsatile flow of, for example, the subject's cardiac or respiratory cycle, or, in the alternative, can be independent of both.
[0198] On the other hand, instead of moving valves, fixed structure valves can be used, such as those found in piezoelectric microfluidic pumps with nozzles. One advantage of valveless pumps is that there are no obvious moving parts to fail like pumps with valves. In addition, nonlinear fluid behavior provides directionality to the flow.
[0199] Flow Control
[0200] In some embodiments, the time-varying flow through the CSF space can be detected (e.g., by a sensor) and the flow adjusted to optimize the performance of the system. Exemplary common flow sensors can include hot wires, membranes, Kalman vortices, Venturi tubes, Pitot tubes, Coriolis flow meters, Doppler sensors, etc.
[0201] For example, any circulated flow, whether CSF is circulated or a structure coated or decorated with an improvement agent is circulated, can be controlled, for example, to be pulse-sensed and / or respiration-sensed. For purposes of illustration and not limitation, control parameters may include: pH, temperature, pressure, local flow rate, mechanical stress, mechanical strain, conductivity, etc.
[0202] The control loop may include algorithms for open loop, feedback loop, feedforward loop, etc. Feedback control may be bang-bang, PID, etc. Advantageously, the system may be analyzed at the system identification level so that the kernel may be developed. Additionally, in some embodiments, disturbance actuation (e.g., a pseudo-random binary sequence pressure sequence) may be imparted to the system for better control.
[0203] In some embodiments of the invention, alarms and safety tracks may be established for parameter values. Exemplary alarms and safety tracks may include pH (e.g., 7.1-7.7), pressure (e.g., 5-15 mm Hg intracerebral pressure (ICP)), physiologically tolerated temperature range (e.g., 34-39 degrees Celsius), etc. In other embodiments, a safety bypass for flow may be incorporated into the structure in the event of a blockage or pump failure.
[0204] In some embodiments, diagnostic parameters can be collected in and by the system. For example, these parameters can include physical parameters (e.g., dynamic, kinetic, and chemical parameters) and parameters used for disease diagnosis or disease research (e.g., using artificial intelligence, big data analysis, etc.).
[0205] Improved system with large flow system
[0206] refer to Fig. 10A and 10B , shows an embodiment of a system 1000, 1000' for improving CSF, which includes a large flow system for actuating CSF flow. Actuation may include increasing the naturally occurring flow of CSF. Increasing may include increasing the phase, direction and / or amplitude of CSF flow. Advantageously, the large flow system can be implanted in a mammalian subject, inside or outside the SAS. In an alternative, substantially all or some portions of the large flow system can be implemented in vitro or in vitro.
[0207] The driving (e.g., active or passive pumping) flow can be completely maintained in the SAS, can be transported out of the SAS and reintroduced into the SAS, and / or can be transported in vitro and reintroduced into the SAS. In some embodiments, the structure 1005 associated with the improving agent and having its own supporting conduit 1010 can be completely implanted in the SAS. For the purpose of illustration and not limitation, the structure 1005 and the conduit 1010 are shown as implanted in the brain SAS 1015 (e.g., the position in the ventricle) rather than in the spinal SAS 1020 (e.g., the position in the lumbar region). In addition, for the purpose of illustration and not limitation, an output port 1025 is created in the brain SAS 1015, and an input port 1030 is created in the spinal SAS 1020. In other embodiments, the input port 1030 can be created in the brain SAS 1015 and the output port 1025 can be created in the spinal SAS 1020, or the input port 1030 and the output port 1025 can be located in the brain SAS 1015, or alternatively, in the spinal SAS 1020. Each port 1025, 1030 may be implemented using a catheter. In some variations, a single port may be used that serves as both an output and input port (eg, using a multi-lumen catheter).
[0208] The macro flow system 1050 can provide fluid communication between ports 1025 and 1030. The macro flow system 1050 can also be implanted in the subject in whole or in part. In some applications, the macro flow system 1050 can include a catheter 1035 through which the CSF flows. The CSF flow can remain in the body or can be transported in vitro, i.e., in vitro. One or more sensors 1040 can be arranged at discrete locations within the pipeline 1035, the macro flow system 1050, and the SAS to provide data signals to the system controller 1045. Typical sensors 1040 can provide data signals of pH, temperature, pressure, flow rate, flow velocity, component concentration, UV radiation, IR radiation, turbulence, Raman scattering, dynamic light scattering, etc.
[0209] Although it is permissible that the CSF flow through the large flow system 1050 can occur at the natural flow rate of the CSF, if active or passive pressure technology is used, pumps 1055, actuators, valves, and combinations thereof can be used to achieve or enhance CSF circulation outside the SAS. In some variations, the pump 1055 may include a peristaltic pump, a rotary vane pump, an Archimedean screw, an air bag, an inflatable bag, a hydraulic bag, a piston pump, an electric pump, a passive pump, an automatic pump, a valveless pump, a bidirectional pump, and combinations thereof. In other variations, the pump 1055 may be similar in principle to a valveless, synthetic jet-based micropump, a bladder pump, and the like. In some applications, algorithms, drivers, and the like executed by the system controller 1045 may control the flow rate and flow rate of the CSF. The control algorithm may be an open loop, feedforward, feedback, and the like. The system controller 1045 may include an open loop controller, a closed loop controller, a PID controller, a PID threshold controller, a system identification algorithm, and the like.
[0210] refer to Fig. 10B , shows a large flow system 1000' that can be substantially disposed within the SAS 1015'. For purposes of illustration and not limitation, the improver 1005' that can be placed within the tube or barrel 1060 has been completely implanted within the brain SAS 1015' (e.g., a position in the ventricle). It will be appreciated by those skilled in the art that in an alternative, implantation can also occur entirely within the spinal SAS (e.g., a position in the lumbar region). In some embodiments, flow actuators 1040a, 1040b can be disposed at opposite ends of the barrel 1060 for the purpose of forcing CSF to flow through the barrel 1060. Although two flow actuators 1040a, 1040b are shown, the flow actuators 1040a, 1040b can also be implemented separately.
[0211] A support conduit 1010' and a communication bus 1065 may also be provided. Although the support conduit 1010' and the bus 1065 are shown to suggest that they are disposed in separate locations, one of ordinary skill in the art will appreciate that a multi-lumen conduit may be used for the support conduit 1010' and the communication bus 1065 so that both are confined to a single conduit location. In some variations, the communication bus 1065 may be configured to provide electrical and electronic communications between the remote system controller 1045' and the flow actuators 1040a, 1040b.
[0212] Introducing improvers through reagent circulation
[0213] In some applications, in addition to introducing the enzyme improver into the CSF (e.g., in the SAS), the improver can also circulate through the CSF instead of remaining stationary or substantially stationary. In some embodiments, the improver can be completely implanted (e.g., via a catheter) in, for example, the SAS and circulate within the SAS; while in other embodiments, the improver can be implanted in a mammalian subject but outside the SAS, from which the improver can circulate in and out of the SAS. As previously described, when the improver is introduced without circulation, the CSF may leave the SAS, circulate through the improver, and return to the SAS.
[0214] refer to Fig.11 In some embodiments, the system or device is implanted below the epidermis 1160 and can include a (e.g., multi-lumen) catheter 1105 that can be implanted entirely within the SAS 1150; preferably, somewhere in or within the SAS 1150 to allow circulation of a structure or support (e.g., a plurality of superparamagnetic beads) 1125 that has been decorated with an improving agent. A supply reservoir 1130 can be located outside the SAS, with the beads 1125 remaining stationary or substantially stationary, while the CSF can circulate (e.g., naturally or using active or passive pumping techniques) through the supply reservoir 1130 to increase exposure and interaction between the CSF and the beads 1125 coated with the improving agent, and the likelihood that the improving agent will enzymatically digest biomolecules within the CSF.
[0215] In yet another embodiment, the improving agent and the structure or support (e.g., beads) to which it is injected or applied can be introduced into or substantially within the SAS and circulated through the SAS, in which case the CSF is not intentionally or artificially driven to move (e.g., by active or passive pumping) except due to natural fluctuations and flows. Advantageously, by this approach, the CSF can be substantially completely maintained within the SAS during improvement, which is desirable.
[0216] Although the embodied structure 1100 will be described with respect to containing beads 1125 in a slurry and circulating the slurry through a multi-lumen catheter 1105 (e.g., mechanically, osmotically, by active or passive pumping, by gas-actuated bellows, etc.), one of ordinary skill in the art will appreciate that, for example, the magnetic properties of the superparamagnetic beads 1125 can help actuate the circulation of the beads 1125 in some applications. Indeed, by placing a magnetic field within the receiving reservoir, the superparamagnetic beads 1125 can be magnetically circulated through the SAS 1150 because the resulting magnetic forces attract the beads 1125. In some variations, the multi-lumen catheter 1105 can include an inner lumen 1110 constructed and arranged within an outer lumen 1115. For example, a closed tip, multi-lumen catheter 1105 (e.g., a spinal catheter or a dialysis membrane catheter) can be used. Advantageously, the multi-lumen catheter 1105 requires a single catheter insertion site.
[0217] Preferably, the outer cavity 1115 can be porous, with pores large enough to allow biomolecules in the CSF to pass through the porous membrane (e.g., about 10-100 nm in diameter) but small enough to contain the beads 1125 (e.g., greater than 1 μm in diameter). Some superparamagnetic beads can range in diameter from about 1 to 3 μm (e.g., the diameter of the superparamagnetic beads from Santa Clara, California). The diameter of LODESTAR beads manufactured by SIGMA-Technologies of St. Louis, Missouri is approximately 2.7 μm); however, other beads may have larger diameters (e.g., Made by Corporation 4B beads, 45-165 μm).
[0218] In some embodiments, beads 1125 that have been decorated with an improving agent can be introduced (e.g., through an access port in a catheter, using a syringe and needle) into a supply reservoir 1130 that can be fully implanted in a subject within a SAS 1150 or preferably outside of a SAS 1150. The beads 1125 can then be introduced (e.g., mechanically, osmotically, by magnetic attraction, by active or passive pumping, by a gas-actuated bellows, etc.) from the supply reservoir 1130 into the lumen 1110. The beads 1125 circulate through the lumen 1110, down the length of the catheter 1105, and then into the space 1120 between the lumen 1110 and the outer lumen 1115 before returning to the receiving reservoir 1135. While flowing in the space 1120 between the lumen 1110 and the outer lumen 1115, the circulating beads 1125 encounter untreated or partially treated CSF. In effect, untreated or partially treated CSF containing biomolecules freely passes through the porous outer cavity 1115 into the space 1120, where it encounters the beads 1125, increasing the interaction between the CSF and the beads 1125 coated with the improving agent, and the likelihood that the improving agent will enzymatically digest the biomolecules within the CSF. Advantageously, the CSF can be retained within the SAS 1150 during the circulation of the beads 1125. The CSF can flow naturally into and out of the conduit 1105, or in some applications, the CSF can be actively or passively pumped while it is in the SAS 1150.
[0219] Beads 1125 can be circulated side by side or coaxially, similar to a continuous countercurrent tangential chromatography configuration. Beads 1125 that have passed through conduit 1105 and have been exposed to untreated or partially treated CSF can be removed from receiving reservoir 1135 (e.g., through an outlet, using a syringe and needle). As previously mentioned with respect to supply reservoir 1130, receiving reservoir 1135 can also be fully implanted in a subject within SAS1150 or preferably outside SAS1150.
[0220] An upper limit on the required volume of improver-coated beads can be estimated by assuming that the DPR concentration is lower than the concentration of the most common CSF neural protein, albumin, which is approximately 69,000 g / mol at 4 x 10 -6 mol / L, which corresponds to a concentration of about 300 mg / L. In contrast, the concentration of the least common CSF neural protein (protein 14-3-3) may be eight to ten orders of magnitude lower than albumin. The concentration of all neural proteins in CSF may fall within 10 -12 Up to 10 -1 g / L range.
[0221] Assuming an average bead diameter of 100 μm and a concentration of 2 x 10 -7 mol / L (concentration of transferrin), a CSF volume of 0.15 L, and a CSF productivity of 0.02 L / hr, the required bead volume is about 250 mL / week. Therefore, there may be about 1.5x10 6 beads / ml.
[0222] In an illustrative embodiment, each bead can have approximately 1 trillion functional reactive groups and a capacity of approximately 1 billion affinity binding proteins per bead; thus, for an assumed concentration, CSF volume, and CSF production rate, approximately 2 x 10 19 At 250 mL / week (about 12 L / year), the number of molecules required is 2 x 10 10 A bead.
[0223] In contrast, the average bead diameter of superparamagnetic beads is approximately 1-3 μm, which is two orders of magnitude smaller than the diameter used in the calculations above. Where r corresponds to the radius of the bead, the ratio of surface area (A) to volume (V) is given by the following equation:
[0224] A / V=4πr 2 / 4 / 3πr 3 =3 / r
[0225] Thus, for a 100-fold decrease in the radius (r) of the bead, the ratio will increase by about 100. Thus, several tens of milliliters of beads would be required per week to clear even albumin-like concentrations of toxins. In contrast, if enzymes were used instead of antibodies, much smaller bead volumes might be required, since the enzymes remain active after the interaction. In practice, the volume of enzyme required depends on the activity of the enzyme (e.g., k_m and k_cat), the flow rate, and the desired conversion of CSF components.
[0226] As an alternative to using and circulating beads through untreated CSF in SAS, a thread-like structure that has been decorated with an improving agent can be introduced into a supply reservoir 1130 (e.g., on a spool-like structure) and passed through the inner cavity 1110 and the outer cavity 1115 to a receiving reservoir 1135, wherein the end of the thread-like structure can be wound (e.g., on another spool-like structure) to pull the thread-like structure decorated with the improving agent through the untreated CSF. Pulling the thread-like structure through the catheter 1105 increases the exposure and interaction between the CSF and the thread-like structure coated with the improving agent, and the possibility that the improving agent will enzymatically digest the biomolecules in the CSF. Multiple strands (e.g., yarn structures) and substrate or reagent support can be used.
[0227] Centralized CSF flow without improver
[0228] In some embodiments, for example, a concentrated and increased flow from a first position in a SAS with a relatively low concentration of toxic biomolecules toward a second position in a SAS with a relatively high concentration of toxic biomolecules may be desired. Alternatively, it may be desirable to transfer from a first position with a high concentration of toxic biomolecules to a second position with a lower concentration of toxic biomolecules. For example, a concentrated CSF flow may be desirable and effective in the SAS, outside the SAS, through the central nervous system and / or from motor neurons in the middle of the brain or the middle of the spinal cord. Preferably, the flow from the first position to the second position can be increased to provide effective treatment without the need for an improver. On the contrary, the flow itself can be adjusted to transport biomolecules from a stagnant position to another position, where the natural, physiological degradation of biomolecules in this other position occurs more effectively. It may also be desirable that a concentrated or increased flow go to or come from an area with a higher density of improvers in the SAS, from or flow to an area with a lower density of improvers in the SAS. Using an automatic bladder pump, etc. may increase natural CSF flow. The characteristics of CSF flow are not only the strong pulsating flow driven by heart and respiratory oscillations, but also the large circulation. The spinal CSF oscillatory motion has a watershed at about the heart level. CSF must have a large flow because obstruction of the ventricular passages can lead to hydrocephalus. Caudal and cephalic movement of CSF has been observed, but the mechanism of this flow is controversial; however, the bidirectional large movement of CSF in the spinal volume (about 1 cm / min) can be explained by the nonlinear cumulative effect of convective acceleration. CSF from the lumbar region enters the cranial vault in about 15-20 minutes, and the time to update the entire CSF volume in the spinal canal volume is several hours. In addition, CSF movement in the cranial volume has different flow rates in various parts of the brain SAS, ranging from 4mm / s to 5cm / s. Since CSF flow is a key component of the subject's natural process of clearing toxic biomolecules, abnormalities in CSF flow may be a contributing factor to the pathogenesis of neurodegeneration. In particular, changes in flushing in specific areas of the SAS may reduce the clearance of toxic compounds and are therefore related to the etiology of many neurotoxic protein-mediated diseases. Therefore, in some embodiments of the present invention, the flow pattern is designed to advantageously address the non-uniform distribution of neurotoxic proteins. In addition, customized flow systems with spatial discrimination can be used to deliver drugs and clear toxic components from the CSF.
[0229] Centralized flow of CSF can be delivered by active and / or passive pumping mechanisms. If a specific flow pattern is desired to address a known disease state and location, a system of catheters and pumps with various flow rates can be implanted to achieve the desired centralized flow pattern. For example, if CSF circulation in the frontal lobe is impaired in a diseased state, an active pump can increase flow to that area. This can be beneficial by itself, but can also be combined with an ameliorative agent. Reasoning for specific flow patterns to accommodate assumed sources and pooling of toxic proteins drives the design of the flow system. Three-dimensional flow fields can be calculated using computational fluid dynamics methods. Example novel circulation pathways include cisternal to cisternal, ventricle to cisternal, and cisternal to lumbar. In addition, multiple parallel circulation pathways can be achieved. Flow can be driven by a passive pump, as described elsewhere in this specification, or by an active pump, or a combination thereof. Aspects of centralized flow are described in Figures 12A to 12D Shown in.
[0230] For example, Fig. 12A Depicts a system for delivering a focused flow through the motor cortex. The system 1200 may include a first catheter 1205 implanted in the cerebral pool, a second catheter 1210 implanted in the brain SAS, such as above the motor cortex, and a passive (e.g., flow-through) pump 1215 that exposes the CSF delivered or transported by the pump 1215 to an improving agent. In some embodiments, an improving agent is not required. The pump 1215 may be implanted inside or outside the SAS.
[0231] Fig. 12B Depicts a system 1200' that imparts focused flow in the spinal canal. The system may include a first catheter 1220a implanted in the lumbar to cervical region of the spinal column SAS in combination with an implanted (e.g., active or passive) pump 1225, which exposes the CSF delivered or transported by the pump 1225 to an improving agent. Likewise, in some embodiments, an improving agent is not required. The pump 1225 may be implanted outside the SAS, and in some variations, may include a subcutaneous inlet and outlet port. Advantageously, the flow may be rostrocaudal or reverse. The relative catheter 1220b may continue the CSF flow circuit within the SAS.
[0232] Fig. 12CA system 1200" is depicted that delivers focused flow from the ventricles to the lumbar sac. The system can include a first catheter (e.g., a ventricular catheter) 1230, (e.g., subcutaneous) catheters 1235a and 1235b, and a third (e.g., lumbar / intrathecal) catheter 1245 in combination with an implanted (e.g., active or passive) pump 1240 that delivers or transports CSF through the pump 1240, i.e., from the second catheter 1235a to the third catheter 1245 (or vice versa) to an exposing agent to an improving agent. The pump 1240 can be implanted outside the SAS, and in some variations, can include subcutaneous access ports. Advantageously, the flow can be anterior-posterior or reverse.
[0233] Fig.12D A system 1200'' is depicted, which may include a first catheter (e.g., ventricular drain) 1250, a lumbar puncture access (e.g., to a spinal volume) 1260, and a waste diverter 1270 (e.g., to a sac) in combination with an implanted (e.g., active or passive) pump 1265 that exposes CSF conveyed or delivered from the first catheter 1250 to the lumbar puncture access 1260 (or vice versa) via the pump 1265 to an ameliorating agent. The pump 1265 may be implanted within the SAS. Advantageously, the flow may be anteroposterior or reverse. In one embodiment, the system may be coupled to Figure 6 These systems ( Figures 12A-12D ) utilizes the architecture of two common procedures (ventricular shunt to peritoneum for hydrocephalus and lumbar drug infusion spinal puncture).
[0234] Filter Method
[0235] In some embodiments, improvement can be accomplished by various filtration techniques or combinations thereof, including but not limited to dead-end (ordinary syringe filters), depth filters, affinity filters, tangential flow filters, countercurrent cascade ultrafilters, and continuous countercurrent tangential chromatography.
[0236] In one aspect of the invention, CSF is improved by a filter or cartridge containing a conversion agent. This treatment can be intermittent or continuous. This promotes the migration of toxic proteins from the interstitial space into the blood volume and then into the CSF, or directly into the CSF in the perivascular space. Once the toxic protein enters the CSF, the circulatory system will remove, degrade or otherwise make the protein non-toxic. Then, the entire system has the effect of producing a high clearance rate of toxic proteins from the brain parenchyma. In another aspect of certain embodiments of the present invention, CSF can be improved by a filter or cartridge containing a conversion agent, thereby promoting the direct migration of toxic proteins from the interstitial space into the CSF. Once the toxic protein enters the CSF, the circulatory system will remove, degrade or otherwise make these proteins non-toxic. Then, the entire system has the effect of highly removing toxic proteins from the brain parenchyma. In one embodiment of the present invention, the filter is of the following types: dead-end filter, tangential filter, continuous chromatography, such as periodic countercurrent chromatography (PCC), multi-column countercurrent solvent gradient purification (MCSGP) and continuous countercurrent tangential chromatography (CCTC) or single-pass tangential flow filtration (SPTFF) or a combination thereof.
[0237] In one embodiment of the invention, the filtration method used by the filter is based on one or more of the following: (1) electromechanical methods, including but not limited to: radio frequency, electromagnetic, ultraviolet radiation, acoustic wave, piezoelectric, electrostatic, nano-, molecular / bio-force, atomic force and ultrasonic filtration and ultrafiltration-based methods; (2) biochemical / physicochemical properties and / or temperature methods, including but not limited to: size exclusion, pore flow, solution diffusion, protein size or secondary, tertiary or quaternary structure, diffusion, hydrophobic / hydrophilic, anionic / cationic, high / low binding affinity, chelators, magnetic or nanoparticle-based systems, and various neurochemical filtration systems; and (3) biospecific affinity methods, including but not limited to specific antibodies, immunotherapy-based, immunomodulatory, ex vivo immunotherapy using immobilized antibodies or antibody fragments, nucleic acids, receptors, anti-bacterial, anti-viral, anti-DNA / RNA, protein / amino acid, carbohydrate, enzyme, isomerase, compounds with high and low biospecific binding affinity based systems.
[0238] In some embodiments, filtration is based on enzymatic digestion using one or more enzymes, which may include: trypsin; elastase; clostripain; calpains, including calpain-2; caspases, including caspase-1, caspase-3, caspase-6, caspase-7, and caspase-8; M24 homologs; human airway trypsin-like peptidase; proteinase K; thermolysin; Asp-N endopeptidase; chymotrypsin; LysC; LysN; glutamyl endopeptidase; staphylococcal peptidase; arg-C protease; proline endopeptidase; thrombin; cathepsins, including cathepsin E, S, B, K, or L1; Tissue Type A; heparinase; granzymes, including granzyme A; methotrexate alpha; pepsin; endothelialase; kallikrein-6; kallikrein-5; and combinations thereof.
[0239] In other embodiments, filtering is based on an affinity approach that relies on the following group of cell surface markers: EpCAM, Notch1, HER2+, EGFR, Heparanase, and Notch1.
[0240] Tangential fluid flow
[0241] In some embodiments, by subjecting the mixture to tangential flow filtration (TFF), the species of interest such as protein or other biological parts are separated from the mixture comprising them. In some embodiments, the filtering process is used to retain the solute of molecular weight between about 1kDa and about 1000kDa. As used herein, the term tangential flow filtration or TFF refers to such a process, wherein the fluid mixture containing the component to be filtered and separated is recirculated at a high speed tangent to the membrane plane to increase the mass transfer coefficient of back diffusion. In this filtration, a pressure difference is applied along the length of the membrane so that fluid and filterable solute flow through the filter. This filtration is suitable for batch process and continuous flow process. For example, solution can be repeatedly passed through the membrane, while (for example, CSF) fluid by the filter is continuously extracted into a separate unit, or solution is passed through the membrane once, and (for example, CSF) fluid by the filter is continuously processed downstream.
[0242] Advantageously, TFF can be classified by particle size, thereby preventing or suppressing filter cake formation, thereby allowing long operation time. In addition, in some embodiments, alternating tangential flow can be used to remove block. Particularly advantageously, TFF overcomes the polarization concentration effect found in traditional filtration, wherein the solute polarization layer is used as an additional filter in series with the original ultrafilter, and significant solvent filtration resistance is provided. In TFF, the feed stream is recirculated at a high speed tangent to the membrane plane to increase the mass transfer coefficient of back diffusion. This fluid flow pattern enhances the retained solute to leave from the membrane surface transmission and return to the feed body. The fluid flowing in the direction parallel to the filter membrane is used to continuously clean the filter surface and prevent non-filterable solute from clogging. In another similar embodiment, the rotary filter device comprises an outer cylinder and an inner cylinder, wherein the inner cylinder is rotated to generate eddy current to obtain high speed without changing pressure. In TFF, the pressure difference gradient, called transmembrane pressure (TMP), is applied along the length of the membrane to make fluid and filterable solute flow through the filter.
[0243] In one embodiment, the high performance tangential flow filtration process described herein comprises passing a mixture of materials to be separated through one or more filter membranes in an apparatus or module designed to perform a type of tangential flow filtration under certain TMP and flux conditions. In particular, the TMP is maintained within a range in the pressure dependency region of the flux v. TMP curve, i.e., within a range of no greater than the TMP value at the transition point. Thus, the filtration is operated at a flux within a range of about 5% to about 100% of the transition point flux. In addition, the filtration is performed such that the TMP is approximately constant over time or decreases throughout the filtration process.
[0244] Maintaining the TMP within this pressure-dependent region results in reduced retention of molecules with molecular weights below the membrane rating and increases the overall selectivity of the system for the species to be purified, thereby overcoming the barrier of the concentration polarization layer. Thus, the species of interest is selectively retained by the membrane as the retentate, while smaller species pass through the membrane as the filtrate, or the species of interest passes through the membrane as the filtrate and contaminants in the mixture are retained by the membrane. It is noteworthy that the TMP does not increase with filtration time and does not necessarily remain constant throughout the filtration process. The TMP may remain approximately constant over time or may decrease as the filtration proceeds. If the retained species is concentrated, it is preferred to reduce the TMP during the concentration step.
[0245] A preferred aspect herein is the use of more than one membrane with the same pore size, wherein the membranes are placed in a stack parallel to each other, preferably one above the other. Preferably, the number of membranes used for this purpose is two, but additional membranes may be added.
[0246] Although the TMP need not remain substantially constant along the membrane surface, it is preferred to maintain the TMP substantially constant. Such conditions are typically achieved by creating a pressure gradient on the filtrate side of the membrane. Thus, the filtrate is circulated through the filtrate compartment of the filtration device in the same direction and parallel to the flow of the mixture in the retentate compartment of the device. The inlet and outlet pressures of the recirculating material are adjusted so that the pressure drop across the filtrate compartment is equal to the pressure drop across the retentate compartment.
[0247] Certain embodiments of the present invention also contemplate a multi-stage cascade process in which the filtrate from the above process is passed through a filtration membrane having a smaller pore size than the membrane of the first device in a second tangential flow filtration device. The filtrate from this second filtration can be recycled back to the first device and the process can be repeated. In this cascade process, the second filtration is typically a conventional filtration in which the flux is maintained at a level greater than about 100% of the filtration point flux; furthermore, typically, the TMP is not maintained substantially constant along the membrane.
[0248] In a more preferred embodiment of the cascade process, both stages involve tangential flow ultrafiltration with pore sizes ranging from 1 to 1000 kDa. In a three-stage cascade process, the filtrate from the second filtration is passed through a filtration membrane having a pore size smaller than the pore size of the second membrane in a third tangential flow filtration device, the filtrate from the third filtration is circulated back to the first filtration device, and the process is repeated. If only two high performance filtrations are required in the cascade process, the third stage can be conventional, i.e., the flux in the third stage is maintained at a level greater than about 100% of the filtration point flux. In a more preferred embodiment of the three-stage cascade process, all three stages involve tangential flow ultrafiltration.
[0249] Exemplary methods can be used to filter substances from the CSF of a human or animal subject. Exemplary methods can include extracting a volume of fluid containing CSF from a space containing CSF in a subject using a filtration system. Exemplary methods can include filtering a volume of fluid into a permeate and a retentate using a first filter of the filtration system, wherein the first filter includes a tangential flow filter. Exemplary methods can include returning the permeate to the space containing CSF in the subject. Exemplary methods can include filtering the retentate using a second filter of the filtration system. Exemplary methods can include returning the filtered retentate to the space containing CSF in the subject.
[0250] In some embodiments, the second filter of the filtration system comprises a dead-end filter or a depth filter. For example, the method may include filtering a plurality of second filters of the filtration system using parallel operation to filter the retentate. In some instances, the method further includes, before returning the permeate and before returning the filtered retentate, combining the permeate and the filtered retentate at the combiner and returning the combined permeate and the filtered retentate to the experimenter's space containing CSF, thereby returning the permeate and returning the filtered retentate. An exemplary system may include a combiner with an inlet coupled to the permeate outlet and the outlet of the second filter. The combiner may be configured to combine the fluid and the retentate filtered by the second filter, wherein the combiner has an outlet for returning the fluid to the experimenter's space containing CSF. In some variations, the system may also include a third filter, the third filter having an inlet coupled to the second retentate outlet, and the combiner is coupled to the permeate outlet, the second permeate outlet and the outlet of the third filter and is configured to combine the retentate, the second retentate of the second filter and the fluid filtered by the third filter. In some instances, the second filter includes a plurality of dead-end filters or depth filters arranged in parallel. In some examples, multiple dead-end filters or depth filters in parallel are self-regulating such that as one of the dead-end filters or depth filters becomes full or clogged, increased pressure causes more waste fluid to be directed to one or more other dead-end filters or depth filters.
[0251] In some applications, the combiner may include a check valve configured to prevent backflow into the second filter. In some variations, the method may also include calculating the waste rate of the filtration system and modifying one or more parameters of the system to maintain a waste rate less than a threshold value. In some instances, the threshold is based on the predicted rate of natural CSF production in the subject. In some instances, the threshold is 0.25 ml of CSF per minute. In some instances, the threshold is 0.20 ml of CSF per minute. In some instances, the second filter of the filtration system includes a tangential flow filter, which is configured to filter the retentate into a second permeate and a second retentate, and returning the filtered retentate to the subject's space containing CSF includes returning the second permeate to the subject's space containing CSF. In some instances, the method also includes filtering the second retentate using a third filter of the filtration system and returning the filtered second retentate to the subject's space containing CSF.
[0252] Substrate countercurrent cascade ultrafiltration
[0253] Another embodiment of the present invention relates to a countercurrent cascade separation system. In some embodiments, the countercurrent cascade separation system may include a series of interconnected levels, wherein each level includes a percolator that receives a flow stream. The percolator in each level is preferentially permeable to the target solute, and the percolator preferentially allows the solute to enter the permeate stream while preferentially retaining the remaining solute in the retention stream. Each level also includes an ultrafilter that receives the permeate stream from the percolator, wherein the ultrafilter selectively permeates the solvent but does not permeate the remaining solute contained in the permeate stream. The various levels of the system are interconnected so that each level after the first level receives a mixed flow stream, which is formed by combining the retention stream and the permeate stream from different levels. The target solute is separated by the countercurrent cascade through the interconnected series of levels.
[0254] In some preferred embodiments, the system can include three interconnected levels. Various preferred systems reclaim the solvent collected by the ultrafilter and return the solvent to the flow stream. In certain embodiments, these systems include at least one level of a macroporous membrane that can evenly distribute the solvent on the percolator.
[0255] Continuous Countercurrent Tangential Chromatography (CCTC)
[0256] Another embodiment of the present invention relates to a system for continuous single-pass countercurrent tangential chromatography with multiple single-pass modules. The single-pass combining step module is used to combine the product from the unpurified product solution with the resin slurry (e.g., permanently, semi-permanently or temporarily). The single-pass washing step module is used to wash the impurities in the resin slurry. The single-pass elution step module for eluting the output of the washing step module is used as a purified product solution. The single-pass regeneration step module is used to regenerate the resin slurry. Preferably, the resin slurry flows through each single-pass module in a continuous, single-pass manner. One or more single-pass modules include two or more stages, and the permeate flow is oriented countercurrent to the resin slurry flow in the single-pass module.
[0257] In some applications, the system includes a plurality of single-pass modules with one or more stages, and each stage includes interconnected tangential flow filters and static mixers. In a preferred embodiment, the single-pass module includes at least two stages and each stage includes interconnected tangential flow filters and static mixers. The chromatography resin flows through each module in a single pass, and the resin is subjected to operations similar to conventional chromatography processes (e.g., binding, washing, elution, regeneration and equilibrium). The buffer for these operations is pumped into the module in the direction opposite to the resin flow; the permeate solution from the later stage is circulated back to the previous stage. This produces a concentration gradient in the permeate solution of the tangential flow filter in the opposite direction to the resin flow direction.
[0258] In vitro improvement systems and methods
[0259] In vitro systems for improving CSF removed from a mammalian subject such as Figures 15A to 15C More specifically, Figures 15A to 15C A partially implantable system 1500 is shown, which includes a cartridge 1515 located outside the body and a fluid communication system 1535, which can be used to remove substances that negatively contribute to and are symptomatic of a disease, such as (e.g., toxic) proteins, cells, etc. For purposes of illustration and not limitation, applications include: neurodegenerative diseases, stroke, and immune-mediated diseases, such as lupus.
[0260] Combination Figures 15A to 15C refer to Fig.16 , showing a method of ameliorating symptoms of a (e.g., neurological or non-neurological) disease. In a first step, a medical professional selects a patient who exhibits one or more symptoms of a particular disease for treatment (step 1). For purposes of illustration and not limitation, these diseases may include: amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTD), progressive supranuclear palsy (PSP), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Guillain-Barré syndrome (GBS), meningitis, cerebral vasospasm, drug overdose, etc.
[0261] At the first position 1505 in the mammalian subject, an outlet port access needle (e.g., waist catheter) can be introduced (e.g., via a subcutaneous access port) into the subject's SAS space (e.g., in the waist CSF space), from which a certain volume of CSF can be removed (step 2). In some embodiments, the volume of CSF removed can be between about 1mL to about 200mL and the removal flow rate can be between about 0.1mL / min to about 100mL / min. The removal flow rate can be controlled by a pumping device 1525, such as any of those active or passive pumps described herein. The volume of CSF removed can be, for example, delivered to and introduced into a cylinder 1515 (step 3) via a pipeline 1510a to be processed in the presence of an improvement agent, an improvement technique and / or an improvement process. In some variations, processing (step 5) can begin immediately, while in other variations, processing can begin (step 4) after the expiration of a predetermined time period. The predetermined time period or time or first waiting period can range from short (in milliseconds to minutes) to long (in one or more hours) to accommodate pump cycle time, cartridge pressure buildup, and / or physiological re-equilibrium time. In some variations, the process can be continuous or substantially continuous.
[0262] Once the removed CSF volume is introduced into the cartridge 1515, the removed CSF volume can be processed (step 5) (e.g., removed, neutralized, digested, converted, isolated, etc.) to improve the biomolecules or toxic proteins (e.g., tau, cis ptau Abeta, TDP-43, SOD1, DPR, neurofilaments, alpha synuclein, etc.) contained or believed to be contained in the removed CSF volume. Preferably, the cartridge 1515 contains an improving agent for treating biomolecules or toxic proteins. The improving agent can be decorated, deposited, attached, adhered to the inner surface of the cartridge 1515; can be decorated, deposited, attached, adhered to beads (e.g., porous, chromatography resin beads, etc.) arranged in the cartridge 1515; and the like. As mentioned above, in some applications, the improving agent may include pin1, living cells, exosomes, enzymes (e.g., trypsin; elastase; cathepsin; clostripain; calpain, including calpain-2; cysteine proteases (caspases), including caspase-1, caspase-3, caspase-6, caspase-7 and caspase-8; M24 homologs; human airway trypsin-like peptidase; proteinase K; thermolysin; Asp-N endopeptidase; chymotrypsin; LysC; LysN; glutamyl endopeptidase; staphylococcal peptidase; arg-C protease; proline endopeptidase; thrombin; cathepsin E, S, B, K, L1; Tissue Type A; heparinase; granzymes, including granzyme A; methotrexate alpha; pepsin; endothelial enzymes; kallikrein-6; kallikrein-5; and combinations thereof) for processing (e.g., by enzymatic digestion) biomolecules or toxic proteins, such as tau, cis ptau, Abeta, TDP-43, SOD1, DPR, neurofilaments, alpha synuclein, and the like.
[0263] Once the removed volume of CSF has been processed within cartridge 1515 (step 5), the processed CSF volume can be returned to the mammalian subject via return conduit 1510b (step 8). More specifically, the processed CSF volume can be returned to the mammalian subject at a second location 1530 (step 8), for example, using an inlet port access needle (e.g., a jugular catheter, a ventricular catheter, etc.) that introduces the processed CSF volume (e.g., via a subcutaneous route) into the subject's SAS space (e.g., into the subject's cervical CSF space, into the subject's ventricular CSF space, etc.). Preferably, pumping device 1525 is further constructed and arranged to return the processed CSF volume to the mammalian subject (step 8) at a flow rate that is the same or substantially the same as the rate at which the CSF volume was removed. Processing of the removed CSF volume may include dual flow capability such that after a volume of CSF is removed from the patient (step 2) and prior to returning the processed CSF to the patient (step 8), the CSF volume may be introduced and bidirectionally or repeatedly sequentially reintroduced into cartridge 1515 to increase residence time and exposure of the removed CSF to the modifying agent in cartridge 1515. Although the various steps of the method are described sequentially, one of ordinary skill in the art will appreciate that when the method is practiced, these steps may and likely will occur simultaneously or partially simultaneously as various volumes of CSF pass through various stages of a particular method.
[0264] The systems and methods described herein are optionally bidirectional, such that at a first location 1505, an outlet port access needle (e.g., a jugular catheter, a ventricular catheter, etc.) can be introduced (e.g., via a subcutaneous access port) into a subject's SAS space (e.g., into a subject's cervical CSF space, into a subject's ventricular CSF space, etc.), from which a volume of CSF can be removed (step 2). Once the removed volume of CSF has been processed within cartridge 1515 (step 5), the processed volume of CSF can be returned to the mammalian subject at a second location 1530 via return conduit 1510b (step 8), e.g., using an inlet port access needle (e.g., a lumbar catheter) that introduced the processed volume of CSF (e.g., through a subcutaneous access port) into the subject's SAS space (e.g., in the lumbar CSF space).
[0265] In some variations, at least one sensing device may be disposed in return conduit 1510b, after cartridge 1515, to capture measurable characteristics of the processed volume of CSF (step 6) as the processed volume of CSF is returned to the mammalian subject (step 8). Alternatively, the sensing device may be disposed in upstream conduit 1510a. Exemplary characteristics of the processed volume may be captured using a sensing device configured to measure one or more of: volume, pressure, temperature, pH, flow rate, etc. Advantageously, data from the sensing device may be transmitted to a control system 1520 (e.g., a microprocessor), which, among other things, receives and processes the data and, in addition, compares the sensed data provided by the sensing device to a predetermined threshold value stored in a memory included in control system 1520 (step 7). Due to concerns about the adverse effects of returning the processed volume of CSF to the SAS space at, for example, a physiologically unacceptable flow rate, pressure, temperature, volume, etc. (i.e., at a rate, pressure, temperature, volume, etc. that may cause harm or discomfort to the mammalian subject), the control system 1520 compares the existing conditions to predetermined thresholds, which can be used by the control system 1520 to control the flow of the processed CSF volume using the communication subsystem to ensure that the operating parameters of the returned CSF are physiologically acceptable. These comparisons and sensed data can be used to update parameters in a set of operating parameters. For example, if the sensor detects an increase in pressure, the pump speed can be reduced, or vice versa in some cases.
[0266] Once the treated CSF volume is returned to the SAS space of the mammalian subject (step 8), the method (step 10) can be repeated until the improvement target is achieved. In some embodiments, a second time period (step 9) must pass before repeating the method (step 10). The second time period or second waiting time period can be a combination of short (in milliseconds to minutes), long (in one or more hours), or variable lengths. For example, a physician may require a treatment regimen that includes substantially continuous CSF filtration for nine hours, repeating the treatment regimen once a day for five consecutive or intermittent days or longer, observing other clinical measurements of the disease, and repeating the treatment once a day for about three months, or more or less.
[0267] Optionally, in addition to the tubing for conduit 1510a and return conduit 1510b, the CSF guiding or circulating system 1535 may include inlet and outlet ports for injecting drugs or introducing boluses into the conduit system and / or for removing waste from untreated or treated volumes of CSF. The CSF guiding or circulating system 1535 may also include one or more of the following: T-valve, stop valve, anti-backflow valve, etc., for controlling the flow of CSF through the conduit. For example, various valves can be used to prevent or minimize unwanted fluid backflow and allow one or more of the following: perfusion, flushing, gas purging, removal of obstructions, maintenance operations (e.g., component replacement), etc. The CSF guiding or circulating system 1535 may also include one or more filtration systems located before or after the cartridge 1515 as a primary or additional treatment method. For purposes of illustration and not limitation, exemplary filtration systems may include: size filtration, ion filtration, tangential flow filtration, countercurrent tangential flow filtration, ultrafiltration, slot filtration, series filtration, cascade filtration, and combinations thereof. As the untreated volume of CSF is removed or the treated volume of CSF passes through the CSF directing or circulating system 1535, the flowing CSF may flow through treatment stations where the CSF may also be subjected to electromagnetic fields, ultraviolet (UV) radiation, heat, bioaffinity interactions (with or without antibodies), etc. Optionally, the bioaffinity interactions may occur with or may be used in combination with manipulating agents (e.g., beads, nanoparticles, optical tweezers, etc.).
[0268] cylinder
[0269] refer to Fig.18 , shows one embodiment of a cartridge 1800 for processing CSF removed from a mammalian subject. In some embodiments, cartridge 1800 may be a commercially available chromatography column 1805, such as that manufactured by Repligen Corporation of Waltham, Massachusetts. MiniChrom (11.3mm x 5mL, REP-001). The barrel 1800 may have a first end to which a first cap 1810 is removably attached (e.g., by friction fit, screwing on, snap-on, etc.), and a second end to which a second cap 1815 is removably attached (e.g., by friction fit, screwing on, snap-on, etc.). Each of the caps 1810, 1815 may include an opening through which a first (e.g., upstream) conduit 1820 or a second (e.g., downstream) conduit 1825 may be inserted to provide fluid communication to and through the barrel 1800. In some embodiments, the internal pressurized space 1830 of the barrel 1800 may be filled with a plurality of (e.g., porous, chromatographic resin) beads 1835 that have been compressed and filled. In order to prevent components from entering or escaping from the barrel, a first filter membrane 1838 may be disposed at the first end of the barrel 1800 and a second filter membrane 1840 may be disposed at the second end of the barrel 1800. In some applications, the improving agent has been decorated on the bead 1835.
[0270] In some applications, cartridge 1800 may be compression packed with a chromatography resin (e.g., agarose, epoxy methacrylate, amino resin, etc.) having a protease covalently bound (i.e., immobilized) to a three-dimensional resin matrix. The resin is a porous structure with a particle size typically between 75-300 microns and, depending on the specific grade, a pore size typically between 100 and 200 microns. between.
[0271] In order to keep the proper function and aseptic of tube 1800, each aspect of tube manufacturing process should be carefully managed.For example, the availability of the active site of the activity or protease digestion target protein of tube 1800 and the inhibition of microbial growth in the resin matrix are important.In some embodiments, particle size can be about 1-50 micron and pore size can be about 8-12 nanometer.In some applications, narrow pore size distribution may be expected, and in other applications, wide pore size distribution may be expected.In other applications again, multimodal distribution of pore size may be expected.
[0272] In the case of cartridge activity, column 1805 is typically filled with a buffer solution for storage. The buffer is intended to inhibit autocatalysis and prevent the reduction of active sites on the available surface area of the resin matrix. An example of a buffer solution that has been successfully implemented is 10 mM HCl with 20 mM CaCl2 at pH 2 and stored at 4°C. In some variations, the buffer may include: PBS 1X can be used as a fixation buffer, ethanolamine 1M, pH 7.5 can be used as a blocking buffer, PBS 1X / 0.05% ProClin 300 can be used as a storage buffer, and HBSS can be used as a digestion buffer.
[0273] Where microbial growth is inhibited, similar components are typically assembled in a clean (e.g., in accordance with ISO 14644-1 cleanroom standards) or sterile environment to avoid the introduction of microorganisms, followed by a sterilization process using validated methods such as gamma radiation, X-rays, UV, electron beam, ethylene oxide, steam, or a combination thereof.
[0274] Another variable that can be controlled to inhibit microbial growth and / or affect enzyme autodegradation inhibition is the pH level of the solution. Solutions with a pH of 2 can be successfully implemented; however, solutions with a pH in the range of about 3 to about 7.5 pH are possible.
[0275] Another variable that can be controlled to inhibit microbial growth is temperature. Chromatography columns are typically stored in a temperature range of 2-8°C, which has been shown to be effective and widely accepted. Storage can be maintained within this temperature range until the cartridge is ready for use.
[0276] The manufacture of cartridge 1800 can be carried out in a clean room (e.g., ISO Class 8) environment at near ambient temperature. The manufacturing process includes filling the resin (with immobilized enzyme) onto the chromatographic column 1805 and packaging it in a double-film polypropylene package. The packaged cartridge 1800 can then be prepared for a sterilization process, which can be gamma sterilization. Gamma sterilization has been determined to be a typical sterilization technique, which is primarily driven by the presence of a liquid buffer. Technologies such as ethylene oxide and steam may be unlikely to fully penetrate and permeate the liquid to achieve the necessary level of sterility. Ideally, cartridge 1800 should be refrigerated as soon as it is produced, and kept refrigerated during transportation to and from the sterilization place. Once the cartridge passes the sterilization process, it can be shipped (e.g., after refrigeration) to the final destination, such as a contract manufacturer or inventory storage area, where it can be stored at 2-8°C.
[0277] In use, the cartridge 1800 can be removed from its temperature-controlled environment and placed at a point of care (POC). At the POC, the cartridge 1800 can be removed from its sterile packaging and subjected to a flushing regimen to wash off the buffer solution and any potentially unwanted residual components, such as unbound enzymes. Flushing or washing mitigates the risk of residual / detached trypsin or other improving agents entering the body when the processed CSF is returned to the subject.
[0278] The flushing scheme may require multiple flushing procedures using different volumes of flushing solutions. Advantageously, the flushing scheme can ensure that any potential residual improvers or enzymes (e.g., trypsin) that can be eluted from the barrel 1800 are flushed away. For example, in some embodiments, the barrel 1800 can be flushed with a solution (e.g., phosphate buffered saline (PBS)) of about one column volume (i.e., 1.0CV). PBS has been shown to eliminate trace amounts of residual enzymes. A larger volume of solution can be used to increase assurance. For example, for a 5mL column 1805, the barrel 1800 can be flushed with 5-6CV (or 25-30Ml). In some variations, in order to more consistently flow through the porous chromatography resin, the temperature of the barrel 1800 can be raised to a temperature higher than ambient temperature. An exemplary flushing scheme can include flushing with 6CV (or 30mL) of PBS, followed by a second flush of 6CV or 30mL of Hanks' balanced salt solution (HBSS).
[0279] In one embodiment, the system can be used to deliver substances through cells or exosomes that have been deposited or decorated on the barrel 1515. The cells or biomolecules used for improvement can be selected based on secreted beneficial molecules (e.g., nutritional factors, anti-inflammatory molecules, etc.) or genetically engineered to produce and release beneficial biomolecules (e.g., with nutritional factors, anti-inflammatory molecules, etc.). Therefore, these beneficial molecules can be used to deliver therapeutic materials (e.g., through CSF circulation) back to mammalian subjects (e.g., brain, spinal cord, etc.). As long as there is a barrier to inflammatory mediators and immune system cells on the barrel 1515, if the cells are otherwise directly implanted in the body, the ex vivo nature of the application barrel 1515 can also prevent or hinder the subject's immune system from attacking foreign cells.
[0280] More specifically, in some applications, the embodiment system 1500 uses exosomes and / or living cells to improve CSF removed from a mammalian subject. Exosomes are vesicles containing, for example, DNA, RNA, proteins, lipids, and miRNA. Exosomes are typically present in the extracellular space and have multiple functions in vivo. For example, it is known that exosomes can be transferred between cells, providing a method for intercellular communication. Exosomes also exhibit protective activity, which is believed to be achieved by releasing proteins from exosomes that have neuroprotective effects. Exosomes isolated from relevant cells known to have protective properties are loaded into the barrel 1515 and the secreted molecules circulate to the brain and spinal cord.
[0281] In some embodiments, the cartridge 1515 in the system can be loaded with exosomes or cells so that when CSF is removed from a subject, the CSF circulates through the cartridge 1515 filled with exosomes or cells, and then when the processed CSF is returned to the mammalian subject, the secreted factors released by the exosomes or cells filled in the cartridge 1515 can be distributed into the CSF and circulate through the brain and spinal cord.
[0282] In some cases, exosomes may also have a negative impact on the disease state. For example, exosomes can promote the transfer of misfolded proteins. Exosomes are also known to be able to penetrate the blood-brain barrier. In this case, these exosomes that penetrate the blood-brain barrier should be removed from the CSF or degraded to reduce their impact on the course of the disease. Studies have also found that the amount of exosomes found in the CSF changes when the disease is present. In some embodiments, the system 1500 can be used to remove unwanted exosomes or cells from the CSF.
[0283] Kits
[0284] In some implementations of the various system and device embodiments described above, packaged kits that include desired or necessary system components and subsystems will be useful. Fig.19 , a block diagram of an exemplary kit 1900 is shown. In some embodiments, the kit 1900 may include devices for a ventricular CSF line, a lumbar CSF line, a CSF circulation system or device 1925, monitoring hardware 1930, and a pumping device 1940. In some variations, the ventricular CSF line may include the following: a peritoneal catheter 1905, a ventricular catheter 1910, one or more catheter adapters, a subcutaneous access port 1920, and a subcutaneous access needle 1935. In some variations, a lumbar CSF line may include the following: a peritoneal catheter 1905, a lumbar catheter 1915, one or more catheter adapters, a subcutaneous access port 1920, and a subcutaneous access needle 1935. In some variations, a second peritoneal catheter 1905 and / or a peritoneal catheter 1905 may be optional, which would allow the lumbar catheter 1915 to be connected directly to the subcutaneous access port 1920 if the lumbar catheter 1915 can reach the lower abdomen of the subject.
[0285] In some embodiments, CSF circulation device 1925 may include cartridge 1800 ( Fig.18 ), one or more pressure sensors (and / or other sensors), one or more sample ports, and pump-specific tubing. Advantageously, cartridge 1800 can be packaged and stored separately. When kit 1900 is needed, cartridge 1800 can be added at the POC. The pump-specific tubing in the CSF circulation device 1925 of kit 1900 can be selected to be compatible with a pumping device (e.g., a peristaltic pump) 1940. Monitoring hardware 1930 may include a programmable microprocessor with a touch screen graphical user interface, random access memory, read-only memory, and programming of a processing unit. Optionally, monitoring hardware 1930 may include a bracket, which may be constructed and arranged to releasably attach pumping device 1940 to monitoring hardware 1930 (e.g., Fig. 15B) and is used to releasably attach the monitoring hardware 1930 to a standard IV pole or similar fixture (such as Fig.15A shown).
[0286] Various advantages of some embodiments of the present invention
[0287] A significant advantage of variations and embodiments of the present invention is the removal of toxic proteins from CSF. Additional advantages and benefits are numerous. For example, a fully implanted device does not require explicit regulation of pressure or temperature while the CSF remains in the body. Furthermore, precise flow control is not required because there is essentially no net flow in the body; therefore, there is no CSF volume change in the subject.
[0288] By completely implanting the construct, the construct is more sterile, more tolerable, more portable and easier to maintain in this setting. With an implanted construct, there is no fluid dead space and no extensive tubing that could become clogged.
[0289] When a flexible structure is introduced into the SAS, its flexible nature allows entry into the body through an opening of smaller diameter.
[0290] Without active pumping, the system may be more robust and simpler in its configuration. For an integral implantable pump, the moving parts may be combined into a single piece, which is simpler and potentially more robust than an external pump system.
[0291] Alternatively, advantages of external systems include the ability to quickly exchange, repair, or adjust components without major disruption, the ability to utilize nonbiocompatible materials such as certain battery power sources, and the ability to be easily configured for greater filtration capacity, flow rate, or power for temperature or pressure control.
[0292] Because treatment and management procedures may be lengthy, once low levels of, for example, DPR are achieved in the CSF, the present invention provides for long-term use, for which less invasive, implantable, removable, low power, low maintenance, and non-constraining attributes are appropriate.
[0293] Alternatively, once low levels of the target protein are achieved, the in vitro system can be detached to allow patient movement and then reattached for additional treatment.
[0294] Embodiments of the present invention can also enable focused or targeted flow to specific areas that require treatment or treatment, for example, before the DPRs are able to affect other locations within the subject's body. For example, if cytotoxicity has been identified in the lumbar region, embodiments of the present invention can be implanted locally in the lumbar region, upstream or near the source of the DPRs, to treat (i.e., focus on) the affected area. This selectivity in locating structures near specific areas provides for zeroing in on problem areas while also reducing the spread of toxin-induced damage through CSF-mediated transport.
[0295] Advantageously, once the structure has been fully implanted, the structure can also be used to sample CSF at will or alternatively in a pseudo-continuous or periodic manner. This feature facilitates long-term monitoring and treatment of a subject. Having a fully implanted structure in a subject can also constitute an independent diagnostic tool.
[0296] Various combinations and permutations of systems, subsystems, components, and related processing methods are contemplated and are considered to be within the scope of the present invention. For example, embodiments of the present invention may include in vitro methods for treating neurological and non-neurological pathologies, neurological and non-neurological trauma, and / or neurological and non-neurological defects. For example, in one embodiment, the present invention can be used to remove toxic DPRs or other biomolecules from CSF, such as by enzymatic digestion, thereby improving neurological or non-neurological pathologies, neurological or non-neurological trauma, and / or neurological or non-neurological defects, such as (for illustration and not limitation): amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTD), progressive supranuclear palsy (PSP), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Guillain-Barré syndrome (GBS), meningitis, cerebral vasospasm, drug overdose, etc.
[0297] In some embodiments, the method may include modifying one or more of the dynamic, kinetic, and / or spatial distribution of the biochemical environment (e.g., fungi, spores, prions, peptides, bacteria, viruses, antigens, blood cells, toxic proteins, dissolved gases, inflammatory mediators, etc.) and / or physical properties of CSF in a mammalian subject (e.g., a human) (e.g., pH, volume, salinity, pressure, concentration, temperature, osmotic pressure, total protein content, etc.). In some applications, the dynamic modification may include improving (e.g., toxic) biomolecules within the CSF by one or more of the following: removing CSF through a shunt, reducing the concentration of (e.g., toxic) biomolecules within the CSF, redistributing (e.g., toxic) biomolecules within the CSF, and / or focusing flow patterns in the CSF. Some embodiments of the dynamic modification may include treatment methods based on implementing physicochemical processes, including one or more of the following: filtration, charge separation, exposure to ultraviolet light, exposure to infrared radiation, exposure to nuclear radiation, Raman scattering, dynamic light scattering, and the like. The kinetic modification may include affecting one or more of flow rate, local flow rate, potential energy, and / or photon or chemical excitation. Spatial modification may include processing biological, chemical and / or molecular components. For example, such processing for the purpose of spatial modification may include separation, degradation, sterilization, irradiation, fixation, isolation, aseptic separation, chemical reaction, molecular reconstruction, depolymerization, local modification, combination of entities, etc.
[0298] Dynamic modification can include treatment methods based on implementing concentrated CSF flow. In some embodiments, concentrated flow can be implemented so that the flow is operable to reduce the concentration of one or more target substances (e.g., biomolecules) at discrete target locations. In other embodiments, concentrated flow can be implemented so that the flow is operable to increase the concentration of target substances at the treatment location. In other embodiments, concentrated flow can be implemented so that the flow is operable to increase the transportation of target species from one location to another.
[0299] In some embodiments involving focused flow, a conditioning cartridge or other structure containing an improving agent may be located outside the subarachnoid space (SAS) while CSF is actively pumped (e.g., via multiple catheters) to and through the external conditioning cartridge and the motor neuron location is presented with highly circulating CSF.
[0300] Spatial modification (e.g., modification of chemical composition) may include the introduction of an improver (e.g., enzyme) operable to enzymatically (e.g., proteolytically) digest the biomolecules in the CSF. In some embodiments, the improver may be introduced into the CSF biomolecules inside or outside the SAS without the circulation of the improver. The CSF may selectively circulate naturally around a stationary or substantially stationary improver, may actively circulate, or may passively circulate. In an example where the improver is substantially stationary, the improver may be arranged on a (e.g., solid) substrate, for example, such that the improver is decorated on the outer surface of a plurality of porous beads, on a porous monolithic structure contained in a cartridge, and the like. The cartridge allows endogenous CSF to flow in, and the endogenous CSF contacts the improver before leaving the cartridge. In some variations, spatial modification may include a combination of an improvement process and / or a combination of an improver. For example, when the improver is combined with the substrate, the CSF may be filtered, subjected to the improver, and then filtered again. In some applications, spatial modification may include a combination of an improvement process plus a concentrated flow and / or a combination of an improver plus a concentrated flow.
[0301] Spatial modification (e.g., modification of chemical composition) may include introducing and circulating improvers that are operable to enzymatically (e.g., proteolytically) digest biomolecules within the CSF. In some embodiments, the improver may be: introduced and circulated entirely within the SAS, introduced and circulated in and out of the SAS, or may be introduced and circulated entirely outside the SAS. For example, in some variations, the improver may be formed on or decorated on the outer surface of a plurality of (e.g., superparamagnetic) beads within a porous bag, a tubular device, and / or a dialysis-like (e.g., dialysis membrane) catheter, which are arranged in the body as a slurry (e.g., in a waist sac). The beads decorated with the improver may circulate within the SAS (e.g., using magnetic attraction, by active pumping, etc.). The CSF may circulate naturally around the circulation improver or may circulate actively or passively.
[0302] Another embodiment may include an in vivo treatment method that includes introducing or placing the improving agent into the SAS (e.g., on a solid, collapsible or flexible substrate or in a tubular structure, tube or catheter) without circulating the improving agent. In various applications, the CSF may circulate naturally (e.g., by passive circulation) in the presence of the improving agent so that the CSF remains entirely within the SAS; the CSF may circulate in the presence of the improving agent by actively pumping the CSF entirely within the SAS; the CSF may circulate in the presence of the improving agent by passively pumping the CSF entirely within the SAS; or the CSF may circulate in the presence of the improving agent by actively or passively pumping the CSF, which may include pumping the CSF from the SAS and back to the SAS.
[0303] The CSF can be circulated in the presence of a (e.g., hydraulically or pneumatically) expandable substrate having a plurality of cilia protruding from the substrate or from a plurality of appendages incorporated into the substrate. Each cilia can be decorated with an improving agent so that as the substrate cyclically expands and contracts, the CSF can mix and any biomolecules within the CSF can interact with (e.g., be enzymatically digested by) the improving agent.
[0304] The CSF can be circulated in the presence of a (e.g., hydraulically or pneumatically) expandable substrate having a plurality of outcropping branches incorporated into the substrate. Each outcropping branch can be decorated with an improvement agent, so that as the substrate cyclically expands and contracts, the CSF can mix and any biomolecules within the CSF can interact with (e.g., be enzymatically digested by) the improvement agent on the outcropping branch.
[0305] The CSF can be circulated in the presence of a tubular structure having a plurality of fibers attached to the inside of a substrate. Each fiber can be decorated with an improving agent and can extend from the inside of the structure and retract into the structure. The biomolecules within the CSF can interact with (e.g., be enzymatically digested by) the improving agent on the fibers in the extended state.
[0306] In a variation, an improving agent is applied to an exposed surface of a stent or plate within a SAS and the CSF is circulated through the stent or plate. In some variations, the CSF is allowed to circulate naturally (e.g., by passive circulation) through the stent or plate. In other variations, the CSF may circulate outside the SAS and return to the SAS before circulating through the stent or plate. Some embodiments of the present invention may include a treatment method that also includes a large flow system having multiple sensors and multiple pumps, valves, and / or actuators that may be controlled by a system controller.
[0307] Other embodiments may include methods for treating a mammalian subject suffering from a neurological or non-neurological pathology, a neurological or non-neurological trauma, or a neurological or non-neurological defect. In some embodiments, the method includes circulating CSF in a subject with a focused flow. In some applications, an improver, an improvement technique, or a combination thereof, is used to improve toxic biomolecules in the CSF. In other embodiments, an improver is not used. In some embodiments, circulating CSF with a focused flow includes: circulating CSF at a natural flow level, allowing CSF to flow out of the subarachnoid space, limiting CSF to flow only within the subarachnoid space, and / or using a passive pump.
[0308] Having described illustrative embodiments of the present invention herein, a person of ordinary skill in the art will appreciate various other features and advantages of the present invention in addition to those specifically described above. Therefore, it should be understood that the above is only an illustration of the principles of the present invention, and that various modifications and additions, including all combinations and arrangements of structural elements and method steps, can be made by those skilled in the art without departing from the spirit and scope of the present invention. Therefore, the appended claims should not be limited to the specific features shown and described, but should be interpreted as also covering modifications and equivalents thereof.
Claims
1. A cerebrospinal fluid (CSF) improving system for fluid communication with a mammalian subject, the improving system for performing a method of treating the subject suffering from at least one of a pathological disease, a traumatic disease, a neurological disease, a non-neurological disease, or a defect characterized by the presence of toxic biomolecules in the CSF, the method improving the toxic biomolecules in the CSF by using an improving agent, the method comprising the following steps: removing a volume of CSF from a first location in the subject at a flow rate between 0.1 mL / min and 100 mL / min, the first location being located in the lumbar sac of the subject; treating the removed CSF volume with the improving agent; returning the processed CSF volume to the subject at a second location, the second location being located in a lateral ventricle of the subject; When the processed CSF volume is returned to the subject, a measurable characteristic of the processed CSF volume is sensed using one or more sensing devices, the measurable characteristic comprising intracerebral pressure, wherein: the intracerebral pressure at the second location is in the range of 5 mm Hg to 15 mm Hg; a plurality of backflow prevention valves controlling the flow of CSF through one or more of the first location and the second location to substantially prevent reverse flow of the fluid; Wherein, the multiple anti-reflux valves include a first anti-reflux valve arranged upstream of a basically rigid balloon catheter and a second anti-reflux valve arranged downstream of the balloon catheter, a T-shaped connector is arranged upstream of the balloon catheter but downstream of the first anti-reflux valve, a pipeline providing fluid communication between a pressure source and an inflatable balloon arranged in the lumen of the balloon catheter is arranged in the T-shaped connector, wherein a tube containing the improving agent is arranged in the lumen of the balloon catheter.
2. The improved system of claim 1 further comprising allowing CSF to flow sequentially or reversibly through the cartridge.
3. The improved system of claim 1, wherein said steps occur at least partially simultaneously.
4. The improved system according to claim 1, further comprising: At least one parameter in a set of treatment operating parameters is updated based on the measured fluid property meeting or exceeding a predetermined threshold, wherein the operating parameter is set to maintain at least one of a specific pressure, a specific volume change, or a specific flow within the CSF space of the subject.
5. The improved system of claim 1, wherein the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), frontotemporal lobar degeneration (FTD), progressive supranuclear palsy (PSP), Huntington's disease (HD), Parkinson's disease (PD), cancer, intracranial metastatic disease (IMD), diabetes, lupus, poisoning, chronic traumatic encephalopathy (CTE), bacterial meningitis, aneurysm, stroke, and cerebral vasospasm.
6. The improved system of claim 1, wherein processing the removed CSF volume comprises removing, reducing, altering, sequestering, digesting, or inactivating at least one of one or more substances selected from the group consisting of tau, cis p-tau, Abeta, TDP-43, SOD1, DPR, neurofilaments, and alpha-synuclein.
7. The improved system of claim 1, wherein processing the removed CSF volume comprises filtering the removed CSF volume using at least one of size filtration, ion filtration, tangential flow filtration, ultrafiltration, slot filtration, in-line filtration, or cascade filtration.
8. The improved system according to claim 1, further comprising the steps of: waiting a first length of time after removing the CSF volume from the subject; and A second length of time is waited after returning the processed CSF volume to the subject.
9. The improved system of claim 1, wherein the improving agent comprises a protease.
10. An improved system according to claim 9, wherein the protease is selected from the group consisting of trypsin; elastase; proteinase K; clostripain; cathepsin; calpain; cysteine protease; M24 homolog; human airway trypsin-like peptidase; thermolysin; Asp-N endopeptidase; chymotrypsin; LysC; LysN; glutamyl endopeptidase; staphylococcal peptidase; arg-C protease; proline endopeptidase; thrombin; Tissue Type A; heparinase; granzyme; methotrexate alpha; pepsin; endothelial enzyme; kallikrein-6; kallikrein-5 and combinations thereof.
11. The improved system of claim 5, wherein the diabetes comprises type 3 diabetes.
12. The improved system of claim 9, wherein the protease is bound to a porous chromatography resin.
13. The improved system of claim 7, wherein the tangential flow filtration comprises countercurrent tangential flow filtration.
14. The improved system of claim 12, wherein said resin comprises porous beads to which said protease is bound.
15. The improved system of claim 12, wherein the resin comprises epoxy methacrylate.
16. The improved system of claim 12, wherein the resin comprises agarose.
17. The improved system of claim 1, wherein the neurological disease is ALS.
18. The improved system of claim 1, wherein the toxic biomolecules in the CSF include TDP-43.
19. The improved system of claim 1, wherein the toxic biomolecules in the CSF include tau.
20. The improved system of claim 1, wherein the toxic biomolecules in the CSF include dipeptide repeat proteins (DPRs).
21. The improved system of claim 1 further comprising using a CSF fluid circuit having a first inlet and outlet port and a second inlet and outlet port to remove the volume of CSF from the first location at the first inlet and outlet port and return the processed CSF volume via the second inlet and outlet port.
22. The improved system of claim 1, further comprising: Measuring fluid properties; determining whether the measured fluid property satisfies a specified relationship to a predetermined threshold over a period of time; and updating at least one parameter of a set of process operation parameters based on the determination, Wherein the treatment operation parameters are updated to maintain at least one of a specific pressure, a specific volume change, or a specific flow rate within the CSF space of the mammalian subject.
23. The improved system of claim 21, wherein said CSF fluid circuit comprises at least one sensor.
24. The improved system of claim 21 further comprising providing a pump and / or valve within the CSF fluid circuit.
25. The improved system of claim 24, wherein the pump is selected from the group consisting of a peristaltic pump, a rotary vane pump, an Archimedean screw, an air bladder, a hydraulic bladder, a piston pump, an electric pump, a passive pump, a valveless pump, a bidirectional pump, and combinations thereof.
26. The improvement system of claim 1, wherein the improvement agent is a therapeutic substance.
27. The improved system according to claim 26, wherein the therapeutic substance is a drug, and the drug includes a secretory molecule having a nutritional factor or an anti-inflammatory molecule, or a nutritional factor or an anti-inflammatory molecule produced by genetic engineering.
28. The improved system of claim 1, wherein the improving agents include enzymes, antibodies, nucleic acids, receptors, amino acids, carbohydrates, compounds with high and low biospecific binding affinity, aptamers, exosomes, molecularly imprinted polymers, and living cells.
29. The improvement system according to claim 1, wherein the improvement agent includes one or more of trypsin; elastase; clostripain; calpain; cysteine protease; M24 homolog; human airway trypsin-like peptidase; proteinase K; thermolysin; Asp-N endopeptidase; chymotrypsin; LysC; LysN; glutamyl endopeptidase; staphylococcal peptidase; arg-C protease; proline endopeptidase; thrombin; cathepsin; Tissue Type A; heparinase; granzyme; methotrexate alpha; pepsin; endothelial enzyme; kallikrein-6; kallikrein-5; pin1 and exosomes.
30. The improved system of claim 1, wherein the neurological disorder is traumatic brain injury.
31. The improved system of claim 1, wherein treating the removed CSF volume comprises neutralizing at least one of one or more substances selected from the group consisting of tau, cis p-tau, Abeta, TDP-43, SOD1, DPR, neurofilaments, and alpha-synuclein.
32. An improved system according to claim 10 or 29, wherein the tissue proteases include tissue proteases E, S, B, K or L1; the calpains include calpain-2; the cysteine proteases include cysteine protease 1, cysteine protease 3, cysteine protease 6, cysteine protease 7 and cysteine protease 8; and the granzymes include granzyme A.
33. The improved system of claim 21 further comprising providing an actuator within said CSF fluid circuit.
34. The improved system of claim 1, wherein the improving agent comprises a protein.
35. The improved system of claim 1, wherein the improving agent comprises an antibody fragment.
36. The improved system of claim 1, wherein the improving agent comprises an isomerase.
